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Medical students attending The George 
Washington University School of Medicine and 
Health Sciences routinely engage in biomedical 
research of a high quality. We are proud to 
present a diverse sampling of these research 
efforts with this publication, authored by our 
fellow medical students for presentation to The 
George Washington University Medical Center 
(GWUMC) community. The articles in the fol-
lowing pages span several disciplines, including 
basic science “bench” research, clinical “bedside” 
efforts, endeavors in global and public health, 
and medical education. From elaborate studies 
of leukemic cells, to new technologies in spinal 
surgery, to health travel experiences in rural 
India, GW medical students continue to impress 
in both the depth and scope of their work.
Putting together this journal was both 
rewarding and challenging. Members of the stu-
dent editorial board, composed of officers of the 
William H. Beaumont Medical Research Honor 
Society, solicited submissions from the medical 
school Classes of 2010 and 2011. We received a 
strong response. The editors and editorial board, 
along with selected faculty, collectively and rigor-
ously reviewed each submission. Responsibility 
for the content of the articles, however, remains 
with the respective author(s). In this second 
edition of Fusion, we are pleased to publish 31 
submissions, reflecting an extraordinary range of 
our peers’ research experiences. 
The Dean’s Office and Office of Student 
Opportunities continually offer superb guidance 
to medical students interested in undertaking 
research, and both deserve special recognition. 
In particular, both offices jointly fostered the 
creation of track programs in research, global 
health, health policy, and medical education, 
among others, to focus student interest and 
generate connections with experienced and tal-
ented faculty—at GWUMC and throughout the 
country. The diversity and quality of research in 
Fusion is a testament to their vision.
We thank James Scott, MD, FACEP, and 
W. Scott Schroth, MD, MPH, in the Office of 
the Dean; Anne Hirshfield, PhD, our faculty 
advisor in the Office of Research; Linda Dent 
and Debbie Goldstein in Medical Center of 
Communications and Marketing; as well as the 
numerous GWUMC faculty members who took 
time from their hectic schedules to review sub-
missions. We also thank the editors of last year’s 
debut edition of Fusion: Andrew Lerner, Vivek 
Patil and Rahul Arya. Their ingenuity, hard 
work and guidance helped lay the foundation 
for the journal you read today. Finally, we espe-
cially thank Thomas Kohout, in the Office of 
Communications and Marketing, for serving as 
our wonderful managing editor, and our editorial 
board for their diligence and hard work.
Medical research is an incredibly exciting 
endeavor, paving the way for important break-
throughs that expand our knowledge of the 
human body and enhance all dimensions of 
patient care. We hope the second annual edition 
of Fusion conveys this excitement to you.
Warm regards,
 from the editors. . .
Andrew H. Gordon, PhD, MSII
Steven V. Kardos, MSII
Ajay Wadgaonkar, MSII 
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 from the dean’s office. . .
While it is indisputable that 
medicine is based on the 
foundations of science, how 
we define that science is any-
thing but narrow in scope and 
quality. Laboratory research, 
clinical studies, community-
based projects and outreach 
across the globe all qualify 
as scientific endeavors, if the 
results of these activities are 
scrutinized in an organized 
way, discussed openly and form 
the beginnings of ongoing 
inquiry. The first step in that 
process is to publish something 
based on the work and begin a 
dialogue about its importance, 
relevance and future directions. In this second 
edition of Fusion, students from The George 
Washington University School of Medicine 
and Health Sciences (SMHS) have gathered an 
impressive collection of contributions that span 
the experiences of scientific endeavors for SMHS 
students. I can say that I’m not only delighted 
to read about the activities of our students, but 
also extremely proud of their many and diverse 
accomplishments.
This journal was conceived by medical 
students in the William H. Beaumont Medical 
Research Honor Society and I commend them 
for their work. Specifically, I want to recognize 
Steven Kardos, Ajay Wadgaonkar and Andrew 
Gordon for their creativity and thoroughness in 
gathering, editing and organizing these projects. 
This journal would not exist without their hard 
work and vision. I also want to thank Associate 
Vice President Anne Hirshfield, PhD, for her 
guidance and mentorship of the Beaumont 
Society and her encouragement of the students 
working on this journal. We are also indebted 
to the Office of Student Opportunities which 
arranged many of these projects for the students, 
and the generous individual supporters in that 
office, specifically Dr. and Mrs. Gerald Lazarus, 
Dr. Christopher Barley, Dr. Keshav Narain, 
Dr. Charles Walkoff and Dr. Robert Rosenberg. 
In addition, none of this would have been pos-
sible without the active involvement of so many 
of our faculty in the research and other activities 
of our medical students. To all of you, a collec-
tive thank you.
I encourage you to take your time as you 
journey through these pages getting a glimpse 
of the variety of activities that are available to 
students at The George Washington University 
School of Medicine and Health Sciences. There 
is no doubt that this school has a unique geo-
graphic location which creates extraordinary 
opportunities for students to participate in ways 
that are much more difficult at other institutions. 
It is also true that, with those opportunities, 
comes a responsibility to discuss our discoveries 
in science, policy and health outreach in an open 
and critical way and to make our findings acces-
sible to a larger audience. This journal, thanks to 
all those who contributed, is a great beginning. 
My congratulations to you all.
James L. Scott, MD 
Dean, School of Medicine and Health Sciences, 
Professor of Emergency Medicine
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 from the research office. . .
It is with great pleasure that I invite readers to 
explore the 2008 edition of Fusion, the second 
volume of a publication that was conceived 
and implemented by officers of The George 
Washington University’s Beaumont Society. The 
William H. Beaumont Medical Research Honor 
Society was established at the GW School of 
Medicine in 1935 to promote student research. 
Although I have the honor of serving as this 
group’s faculty advisor, the Society is entirely 
student run. 
Fusion came into being because Beaumont 
Society officers wanted a vehicle for capturing 
and preserving the variety of experiences students 
had while carrying out research rotations and 
summer research projects, activities that many of 
our students undertake during their pre-clinical 
years. The officers wanted to communicate the 
excitement and value of these experiences to 
a wider audience. Last year’s first edition was 
received with great enthusiasm and, as a result, 
members of the Society have decided that the 
publication should become an annual tradition. 
This project is entirely student driven, and 
therefore a real testament to the students them-
selves who devoted a tremendous amount of 
time and effort to its production. Considering 
the demands of their medical education, this 
publication represents an outstanding achieve-
ment for those involved. In acknowledging all 
those who made this second volume of Fusion 
a reality, thanks go to the Office of Medical 
Center Communications and Marketing, who 
contributed their expertise in assuring the 
professional appearance of this publication. 
Acknowledgements and thanks are also due 
to the faculty research advisors who welcomed 
the student researchers into 
their programs and mentored 
their research activities and 
progress. Finally, we need to 
recognize contribution of the 
W.T. Gill Endowment, which 
provided summer stipends for 
most of the students whose 
work is described in this 
journal. Our gratitude for this 
invaluable resource cannot be 
overstated.  
Many of the students 
whose work appears on these 
pages are among the best and 
most enthusiastic in their 
class. Some will undoubtedly 
go on to careers in research, 
joining the ranks of our many GW alumni who 
have made major contributions to collective 
knowledge about improving the health and well 
being of humankind. Others will not choose a 
research career, but will make their contributions 
in the clinical realm or in other forms of service. 
Whatever the future holds for these talented and 
dedicated students, their research experience 
will remain with them for the rest of their lives, 
informing their understanding of the nature and 
pursuit of knowledge. 
Anne N. Hirshfield, PhD 
Associate Vice President for Health Research
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 basic science. . .
What Role Do Androgens Play in Bone Growth?
Osteoporosis causes deterioration of bone tissue, 
resulting in an increased fragility of bone and 
corresponding increased risk of pathologic bone 
fracture. Osteoporotic bone fracture, therefore, 
has become a serious public health dilemma 
and a leading cause of disability worldwide.1 
Studies suggest a link between osteoporosis and 
a hypogonadal state, potentially with reduced 
amounts of circulating androgens, in both men 
and women.2,3 Therefore, androgens could play 
a role in the treatment of osteoporosis, yet the 
specific role of androgens in bone growth and 
maintenance remains unclear.
Hypogonadal elderly men appear to benefit 
from anabolic steroid treatment, developing 
increased lean body mass and gradual, yet 
progressive, increases in bone mineral density 
(BMD).4 In a separate study, treating severely 
burned children with the androgen oxandrolone 
also increased BMD within three to six months.5 
However, studies of anabolic steroid abuse in 
developing teenagers suggest stunted growth as 
Adrian A. Woo, MSI
Principal Investigator: 
Kristine M. Wiren, PhD 
Oregon Health Sciences 
University, Portland, OR
a result of premature closing of the epiphyseal 
growth plate in bone.6,7 Thus more definitive 
studies are necessary to elucidate the role of 
androgens in bone growth and maintenance.
To examine specific androgen effects on bone, 
we genetically altered androgen receptors (ARs) 
otherwise normally present in F2 populations* 
of inbred mice. ARs in specific populations of 
osteoblasts were altered using different sections 
of the type I collagen promoter coupled to a rat 
AR gene sequence. A 3.6-kb portion of the type 
I collagen promoter directed AR expression in 
osteoblasts throughout the lineage, from bone 
marrow mesenchymal stem cells through to 
mature osteoblasts, while the 2.3-kb compo-
nent targeted only the mature osteoblasts.8 AR 
overexpression in male AR3.6-transgenic mice 
exhibited a complex phenotype, notably increased 
trabecular bone mass caused by reduced osteo-
clast activity. Also, cortical bone expansion was 
observed due to periosteal bone surface expan-
sion, but without increased endosteal deposition. 
Femoral long bones of male AR3.6-transgenic 
mice demonstrated a more brittle phenotype, 
partially attributable to inhibition of bone growth 
on the endosteal surface.9
Overexpression of ARs in mature osteoblasts 
mimics the high level of endogenous AR expres-
sion documented at this stage of differentiation.10 
High-resolution micro-computed tomography 
showed no differences in total cross-sectional 
area. Cortical bone width and area were reduced 
with increased marrow cavity in male AR2.3-
transgenic mice. These femurs also showed 
decreased biomechanical strength and quality in 
4-point bending tests, as indicated by significant 
decreases in stiffness and maximum load, as well 
as more dramatic decreases in post-yield deflec-
tion (brittleness) and work-to-failure (data not 
shown). Dynamic histomorphometric analysis 
at eight weeks showed predominantly decreased 
endosteal labeling, with corresponding decreased 
periosteal and increased endosteal resorption 
(Figure 1C, D). Decreased bone formation and 
mineral apposition rates on the endosteal surface 
indicated that bone creation on this surface 
FIGURE 1: RATES OF BONE FORMATION IN MALE AR2.3-TRANSGENIC 
MICE BY DYNAMIC HISTOMORPHOMETRY. After femurs were sectioned and polished 
to 40 mm, sections were subjected to fluorescent microscopy and labels were measured. A. Bone formation 
rate. B. Mineral apposition rate. C. Percentage of eroded surface. D. Percentage of labeled perimeter. Labels 
were measured at both periosteal and endosteal surfaces and show a significant lack of endosteal labeling 
in male AR2.3-transgenic mice. Data is shown as mean ± SEM. n = 8-20. *, p < 0.05 **, p < 0.01; ***, 
p < 0.001 (vs. gender-appropriate wild-type controls).
BONE GROWTH Continued on p. 7
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was significantly inhibited, while the periosteal 
surface was not significantly affected in this 
way (Figure 1A, B). These results indicate that 
effects of androgens differ at these surfaces, and 
are inhibitors of growth rather than anabolic 
in mature bone. This study, therefore, suggests 
androgen use in treatment of osteoporosis in fact 
could be deleterious rather than beneficial.
REFERENCES:
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osteoporotic fractures. Lancet, 2002; 359:1761–67.
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* F2 GENERATION 
MICE were obtained by the 
mating of F1 generation mice 
showing the desired trait.  The 
gene was inserted into the 
embryos of mice from a line of 
inbred mice from Jackson Labs.
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Antiproliferative Properties of Thymosin Fraction 5 
in HL-60 Human Promyelocytic Leukemia Cells
For decades, the thymus gland was thought to 
be a functionless, vestigial organ in mammals. 
Through the pioneering work of Jacques Miller 
in the early 1960s, the thymus became appreci-
ated for its vital roles in maturing T-cells and 
establishing the immune system. Shortly there-
after, Goldstein and White described the isola-
tion of a family of hormone-like peptides from 
the thymus gland collectively called thymosins.1 
Since then, these small, biologically active pep-
tides have been shown to possess important roles 
in diverse physiological processes ranging from 
immunomodulation to wound healing. 
Interestingly, a number of these thymic pep-
tides have anti-proliferative effects on various 
human and murine tumor cell lines. This 
finding, along with age-related correlations of 
thymic involution and an increased frequency of 
cancer, has led some to hypothesize the thymus’s 
role in a possible immune surveillance mecha-
nism of cancer suppression. Most recently, this 
idea was explored in HL-60 human promyelo-
cytic leukemia cells.
Ali A. Damavandy, MSI, 
Research Track
Advisor: Mahnaz Badamchian, 
PhD, Department of 
Biochemistry, The George 
Washington University Medical 
Center, Washington, DC
HL-60 cells were initially derived from a 
patient with acute promyelocytic leukemia, a 
disease in which myeloid precursors undergo 
rapid proliferation without differentiating into 
mature cellular elements. This uncontrolled 
growth results in an accumulation of these non-
functioning cells in bone marrow and blood, 
displacing their mature, active forms, ultimately 
leading to systemic complications. Previous work 
demonstrated the ability of thymosin fraction 5 
(TF5), a partially purified protein extract from 
bovine thymus, to substantially suppress the pro-
liferation of HL-60 cells in both concentration 
and time-dependent manners by what appears 
to be a distinct, non-lethal cytostatic mecha-
nism.3 Present efforts have been aimed at further 
purifying TF5 in order to isolate the effector 
peptide(s) responsible for this suppressive activity.
Purification by fast protein liquid chroma-
tography (FPLC) followed by further purifica-
tion by reverse phase high-performance liquid 
LEUKEMIA CELLS Continued on p. 8
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chromatography (RP-HPLC) has yielded a sub-
fraction of TF5 which retains the anti-prolifera-
tive activity of the parent extract. The near-term 
goals of this work are to sequence and chemically 
characterize this peptide as well as to see if its 
biological activity can be reproduced with a syn-
thetic version of the molecule. Interestingly, the 
latest flow cytometry data obtained indicates that 
a significant number of the suppressed leukemic 
cells do indeed undergo apoptosis. Ultimately, 
elucidating the mechanism by which this peptide 
exerts its action will be helpful in determining 
whether it has real therapeutic potential. 
REFERENCES:
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SHROFF S, BADAMCHIAN M, JOHNSON CR, JARVIS WD. Presence 
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human promyelocytic leukemia cells. Int Immunop-
harmacol, 2005; 5:1317–29.
4. SPANGELO BL, ROACH JD, HADI F, DAMAVANDY AA, PLIESKATT J, 
BADAMCHIAN M. Thymosin fraction-5 possesses antipro-
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Apoptosis is the scientific term for the genetically 
programmed process of cell death.1 The Bcl-2 
family of proteins, which includes both pro- and 
anti-apoptotic members, is responsible for the 
regulation of apoptosis through control of caspase 
activity.1 Bcl-2 
protects cells 
from apoptosis 
by inhibiting Bax 
and Bak (both 
pro-apoptotic 
members) from 
releasing cyto-
chrome c, an 
important co-
factor for caspase 
activation, from 
mitochondria.2 
Previously, Bcl-2 
was thought to 
be subcellularly 
localized only 
to mitochondria, however, recent work suggests 
that Bcl-2 is distributed in the rough endoplasmic 
reticulum (ER) as well.3 Prior in vivo studies have 
shown that overexpression of wildtype Bcl-2 pro-
tects against ethanol toxicity, a known inducer of 
apoptosis.4,5 Currently, it remains unclear whether 
ethanol toxicity protection is mediated through 
mitochondria or inside the ER. 
Our team investigated whether the already 
known in vivo protection from ethanol is medi-
ated through ER-Bcl-2 or mitochondria — Bcl-2. 
The team used three 
different fusion 
constructs encoding 
for green fluorescent 
protein (GFP): Bcl-2 
fusion proteins were 
used to examine the 
Bcl-2 subcellular 
localization and 
determination of 
differential rescue 
from ethanol. A 
line of Chinese 
hamster ovary cells 
(CHO695) was 
transiently trans-
fected with GFP: 
Bcl-2 wildtype plasmid, GFP: Bcl-2 MAOB 
(mitochondria target) and GFP: Bcl-2 Cb5 (ER 
target). Fluorescence microscopy was employed 
to verify the localization of the GFP: Bcl-2 
ER-Targeted Bcl-2 Mitigates Ethanol Toxicity More Significantly 
than Wildtype or Mitochondria-Targeted Bcl-2
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FIGURE 1: ER-targeted Bcl-2 rescues CHO695 from 24 hours of ethanol 
incubation more significantly than mitochondria or wildtype-targeted Bcl-2. 
Student’s t-test was used to assess data significance. n=32; (*), (**) and (***) 
indicate significant results with a p<0.05, p<0.01 and p<0.001, respectively. Data 
are shown as means ± standard error. 
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fusion proteins. Apoptosis was examined in 
response to ethanol in the presence of wildtype 
Bcl-2 or organelle-targeted Bcl-2 using the MTT 
apoptosis assay. We tested whether the subcel-
lular localizations of Bcl-2 to the ER and the 
mitochondria would confer different levels of 
rescue against ethanol toxicity. GFP: Bcl-2 fusion 
proteins were appropriately localized, indicating 
successful organelle-targeting. Our in vitro 
model system confirmed the protective role of 
Bcl-2 wildtype against ethanol toxicity previ-
ously shown only in vivo.4,5 Moreover, we found 
that the ER-targeted Bcl-2 significantly rescued 
CHO695 cells from ethanol toxicity, even at 
normally toxic concentrations, whereas wildtype 
and mitochondria-targeted Bcl-2 offered more 
limited protection (Figure 1). The same results 
were confirmed in another line of Chinese ham-
ster ovary cells (CHO-Pro5) as well.
Therefore, our findings indicate that Bcl-2’s 
known amelioration of ethanol toxicity is likely 
mediated through pathways in the ER. Such 
results could be utilized to elucidate a pos-
sibly new apoptotic pathway in which the ER 
is upstream of the mitochondria and in which 
Bcl-2 embedded in the ER membrane inhibits 
ETHANOL TOXICITY Continued from p. 8 Bax translocation to the mitochondria. Research 
attempting to understand cellular changes 
induced by ethanol toxicity, and aiming to 
exploit a cell’s own defense mechanism, could 
ultimately lead to treatments preventing alcohol 
toxicity. 
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Breast cancer is the most common malignancy 
seen in women. As many as one-third of women 
with early-stage breast cancer will die, with 
most developing complications arising from 
bone metastases, including severe pain, spinal 
cord compression and pathologic fracture.1,2 In 
conjunction with the Center for Musculoskeletal 
Research and Department of Biomedical 
Engineering at the University of Rochester 
Medical Center, a novel way of suppressing this 
tumor burden in bone was discovered.
This required a tremendous appreciation for 
bone biology and how certain breast cancers 
prefer particular metastatic sites. In fact, some 
breast cancers uniquely display osteotropism, a 
significant ability to proliferate in bone.1 These 
breast cancers with a preference for bone and the 
potential host metastatic site must each possess 
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NF-κB Gene Suppression
Andrew H. Gordon, PhD, MSII 
Advisor: J. Edward Puzas, PhD 
Co-Collaborators: Regis J. 
O’Keefe, MD, PhD; Edward M. 
Schwarz, PhD; Randy N. Rosier, 
MD, PhD, Orthopaedic Research 
Laboratories and Department 
of Biomedical Engineering, 
University of Rochester 
Medical Center, Rochester, NY
intrinsic biological properties favoring mutual 
attraction between one another.3 As early as 1889, 
Paget put forth the “seed and soil” hypothesis 
that embodies this phenomenon, referring to the 
bone microenvironment as a fertile, rich “soil” in 
which breast cancer cells may grow as “seeds.”4
A clinical hallmark of disrupted bone remod-
eling in aggressive breast cancers is osteoclast-
mediated bone destruction.1 Osteoclasts are 
bone-resorbing cells native to bone which are 
activated in response to cytokines produced by 
breast cancer cells.5 Production of these cytok-
ines is tightly controlled by the nuclear factor-κB 
(NF-κB) transcription factor.6
Targeting the NF-κB pathway holds signifi-
cant promise in treating various cancers and 
BREAST CANCER Continued on p. 10
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FIGURE 1: THE “VICIOUS CYCLE” OF CANCER-MEDIATED BONE 
DESTRUCTION. Chemical interactions between SDF-1a/CXCL12 and CXCR4 influence breast cancer 
cells to home in on bone, adhere to the bone linings and seed in the bone microenvironment. The tumor 
cells then secrete cytokines (i.e., PTHrP, TNFa, IL-1, IL-6, and IL-11), many of which are controlled by 
NF-κB signaling. This stimulates bone resorption by osteoclasts via osteoblast production of RANKL. Matrix 
metalloproteinase (MMP) production by tumor cells, also controlled by NF-κB signaling, also directly degrades 
bone. This bone destruction in turn releases from the bone matrix growth factors capable of stimulating tumor 
cells to destroy more bone, creating sustained “vicious” cycles of tumor-mediated bone resorption.
diseases associated with abnormal bone resorp-
tion.7,8 Since patients with bone cancers possess 
much lower relative survival rates than patients 
with soft tissue cancers,9 verifying a target such 
as NF-κB, governing production of an array of 
biological factors relevant to metastatic progres-
sion in bone, can be of great value.
The bone-seeking MDA-MB-231 
breast cancer cell line was genetically 
altered to suppress NF-κB-mediated 
gene expression. In its inactive 
state, NF-κB is bound to an IκB 
protein within the cytoplasm of 
cells. Phosphorylation of IκB frees 
NF-κB to move to the nucleus of cells 
to perform NF-κB-mediated gene 
transcription.6 A single-point mutation 
of IκB (replacing one serine amino 
acid for an alanine) was stably infected 
in these breast cancer cells to prevent this 
phosphorylation and associated gene expression.10 
Blocking NF-κB signaling in MDA-MB-231 
cells decreased in vitro cell growth, expression 
of the proinflammatory, bone-resorbing 
cytokine interleukin-6 (IL-6), and in vitro bone 
resorption by tumor/osteoclast co-cultures 
while reciprocally up-regulating production of 
the apoptotic enzyme caspase-3. Suppression 
of NF-κB transcription in these breast cancer 
cells also suppressed in vivo tumor-mediated 
bone destruction after intratibial injection of 
tumor cells in female immunosuppressed mice. 
Immunohistochemistry showed the resorptive 
lesions formed in bone by MDA-MB-231 cells 
express both the p65 subunit of NF-κB and IL-6 
at the bone-tumor interface.10 Taken together, 
these findings demonstrated an essential role 
for NF-κB signaling in breast cancer-mediated 
bone destruction. Strong rationale now exists to 
further investigate genetic and pharmacologic 
NF-κB inhibitors as standard or adjuvant 
therapies in these regards.
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Targeting the NF-κB 
pathway holds significant 
promise in treating var-
ious cancers and diseases 
associated with abnormal 
bone resorption.7,8 
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Certain Piperazines Mimic Stimulant or Hallucinogenic 
Effects of Ecstasy
Users of 3,4-methylenedioxymethamphetamine 
(MDMA, “ecstasy”) report the drug elicits 
a complex array of subjective effects, some 
stimulant-like and others hallucinogen-like.1 
Usage of MDMA has increased worldwide, 
particularly among young adults.2 While 
regulatory control of MDMA exists in the 
United States, federal law enforcement agents 
continue to encounter and confiscate MDMA 
across the country.3 In addition to widespread use 
of MDMA itself, certain “ecstasy” tablets also 
contain N-substituted piperazines which mimic 
the effects of MDMA.4 
This study investigated how certain 
N-substituted piperazines, in comparison with 
MDMA enantiomers, may affect classical 
stimulant and 
hallucinogenic 
behaviors in 
mice trained to 
discriminate either 
S(+)-MDMA or 
R(-)-MDMA from 
saline. Previous 
studies suggest 
that the effects of 
S(+)-MDMA are 
more stimulant-
like than those of 
R(-)-MDMA, while the actions of R(-)-MDMA 
are more hallucinogen-like than those of the 
S(+)- enantiomer.5
In a murine model, various N-substituted 
piperazines were administered and evaluated 
for head twitch response (a hallucinogen-like 
drug effect), increased locomotor activity 
(a stimulant-like drug effect) and MDMA-
like discriminative stimulus effects in mice 
(analogous to subjective drug effects in humans). 
Various doses of l-benzylpiperazine (BZP), 
1-(3-trifluoromethylphenyl) piperazine (TFMPP), 
1-(3-methoxybenzyl) piperazine (m-MeO-BZP) 
or meta-chlorophenyl piperazine (m-CPP) were 
administered to mice to determine the effects on 
these behavioral endpoints. 
The head twitch response is sensitive 
to serotonin 5-HT2 agonist activity in the 
rodent and was therefore used to evaluate the 
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hallucinogen-like effects of BZP, MeO-BZP, 
TFMPP, and m-CPP.6,7 All N-substituted 
piperazines were tested for locomotor stimulant 
effects in a modified open field apparatus, and 
mice trained to discriminate S(+)-MDMA 
or R(-)-MDMA from saline were tested for 
stimulus generalization to all of the N-substituted 
piperazines. 
The results of the current study indicated 
that BZP, TFMPP, and m-CPP dose dependently 
could fully substitute for S(+)-MDMA, but could 
not elicit R(-)-MDMA-like stimulus effects. In 
contrast, m-MeO-BZP dose dependently could 
partially substitute for both enantiomers. BZP 
profoundly stimulated locomotor activity, but did 
not elicit a significant head twitch response, while 
TFMPP elicited a dose dependent head twitch 
response but only suppressed locomotor behavior. 
Neither m-MeO-BZP nor m-CPP elicited head 
twitch behavior, as both compounds decreased 
locomotor activity dose dependently.
Of all the N-substituted piperazines studied, 
only BZP exhibited a clear stimulant-like 
pattern of behavioral effects, while only TFMPP 
exhibited hallucinogen-like effects in the head 
twitch assay. Based on the present findings, 
m-MeO-BZP and m-CPP cannot be described 
as stimulant-like or hallucinogen-like in the 
mouse. Still, various N-substituted piperazines 
demonstrate differing ecstasy-like drug effects 
in a murine model, and warrant further 
investigation and monitoring with regard to their 
addiction and abuse potential.
ECSTASY Continued on p. 12
FIGURE 1: SUMMARY OF EXPERIMENTAL RESULTS. 
 Drug Head Twitch Locomotor S(+)-MDMA R(-)-MDMA 
    Discrimination Discrimination
	 BZP	 No	 Increase	 Full	 None
	 MeO-BZP	 No	 Decrease	 Partial	 Partial
	 TFMPP	 Yes	 Decrease	 Full	 None
	 m-CPP	 No	 Decrease	 Full	 None
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A fundamental organizational feature of the 
mammalian brain is the arrangement of sensory 
representations in the cerebral cortex. The 
cortical representation of vision is localized 
in the occipital lobe, auditory in the temporal 
lobe and somatosensory in the parietal lobe. 
Studies of a wide variety of mammals indicate 
a primary thalamic-recipient area for each 
sensory modality, designated as the primary 
sensory cortex. Most textbook depictions of the 
sensory representations show a large gap between 
locations of the primary sensory representations. 
However, these areas are not inactive, but rather 
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they vigorously process sensory information. In 
fact, the sensory cortical organization of higher 
mammals is one in which primary processing 
areas are typically surrounded by secondary or 
higher-level processing areas. 
In the cat brain, the lateral suprasylvian 
sulcus (LSS) contains representations of the 
visual modality thought to be exclusively 
populated by visual-specific neurons.1,2 The 
visual LSS is laterally bordered by the dorsal zone 
of auditory cortex; recent electrophysiological 
experiments document the presence of auditory/
visual bimodal cells in what otherwise 
appears to be the visual 
LSS.3,4 While the sensory 
function of the LSS 
cells has been 
expanded with 
this finding, 
the transition/
multisensory 
zones between 
auditory and 
visual regions have 
not been defined. It 
is not known whether 
AUDITORY 
PROJECTIONS 
 Continued on p. 13
FIGURE 1. ORTHOGRADE PROJECTIONS FROM AI TO LSS. Injections of tracer 
result in labeled axons and terminals in the lateral bank of the LSS. Coronal sections are arranged from the 
left, anterior to posterior. Grey regions indicate location and extent of injection; each black dot represents 
a single bouton or axon terminal. Inset on left indicates the cortical level from which each coronal section 
originates. Scale bar = 1mm.
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there is a distinct border marking the edge 
between the two different representations, or if 
there is a gradual transition yielding a substantial 
area in which representations of both modalities 
overlap. In the latter case, inputs from different 
modalities that overlap within a given area 
can converge onto individual neurons, thereby 
inducing multisensory properties.5 
This problem was addressed in our study by 
labeling auditory projections to the LSS of the 
cat using neuroanatomical tract tracing methods. 
Adult cats (n=17) were anesthetized and, 
using sterile surgical techniques, biotinylated 
dextran amine (BDA) was injected into one of 
the following auditory cortical areas: anterior 
auditory field (AAF), primary auditory cortex 
(AI) or posterior auditory field (PAF). Standard 
cytochemical procedures were used to visualize 
the transported tracer and a computer-based 
digitizing microscope was used to plot the 
location of labeled axon terminals. In each 
case, labeled boutons were identified in the LSS 
region. Labeled terminal boutons were most 
concentrated at the outer lip of the LSS and the 
label became progressively reduced with depth 
along the lateral bank of LSS toward the fundus, 
as shown in Figure 1, for AI auditory projections 
to the LSS (each black dot=1 labeled bouton). 
This steady decrease in auditory projections 
down the bank of the LSS, as opposed to 
an abrupt demarcation, indicates a gradual 
transition from auditory to visual sensory 
modality.
Although the LSS has widely been regarded 
as a visual area of the cat cortex, these results 
show that multiple auditory cortical projections 
target the region in a gradated manner. Auditory 
projections are quite dense at the external lip of 
the sulcus and are gradually reduced within the 
depth of the bank of the LSS. Ultimately, the 
broad distribution of auditory input suggests that 
substantial portions of the visual LSS region may 
be a site of multisensory (visual and auditory) 
convergence. These overlapped projections may 
provide the anatomical basis for multisensory 
properties of neurons in higher mammals. 
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A Role for Chemokine Gene Variants in Muscle Strength?
The overarching goal of the Bone Health 
Program at Children’s National Medical 
Center, in Washington, DC, is to contribute 
answers to the questions, “What makes bone 
strong?” and “can we make bones stronger?” 
More specifically, the program seeks to identify 
genetic variations that will help individuals 
better understand their risks for bone health and 
disease, while simultaneously providing them 
with recommendations for healthy behaviors that 
can reduce their risks of serious 
disease. To help achieve this goal, 
the Bone Health team partnered 
with Dr. Eric Hoffman, director 
of the Research Center for Genetic 
Medicine, to develop a program 
that explores answers to these 
questions in the clinic, operating room and 
laboratory.
Our Gill Fellowship summer projects were 
devoted to the study of chemokines. Chemokines 
are a large group of proteins that act as lures 
to attract white blood cells and are involved 
in various disease processes, including acute 
and chronic inflammation, infectious diseases 
and cancer. Although primarily associated 
with disease, the inflammatory response is also 
associated with muscle repair, regeneration and 
growth.1 Muscle strength, as well as exercise, 
contributes to bone strength. The CC family of 
chemokines is the largest of its kind, and one of 
the most thoroughly characterized chemokines 
is CCL2.1 CCL2 and one of its major receptors, 
CCR2, are encoded by genes CCL2 and CCR2, 
respectively. Given the widespread effects of 
CCL2 and CCR2, our goal was to investigate 
whether variants of the genes CCL2 and CCR2 
influence skeletal muscle, bone and subcutaneous 
fat volume at baseline and after resistance 
training in healthy young adults.
Blood DNA samples and MRI images were 
obtained from the Functional Polymorphisms 
Associated with Muscle Size and Strength 
study of more than 1,200 college students 
enrolled in a 12-week resistance training 
program. Investigating the influence of genetic 
polymorphisms on bone geometry, fat volume, 
and skeletal muscle size and strength, variants in 
CCL2 and CCR2 were found to correlate with 
specific skeletal muscle and subcutaneous fat 
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volume phenotypes. Although the study cohort 
had not participated in resistance training for 
one year, we found that individuals with the 
rare alleles consistently had the greatest baseline 
muscle strength and lowest subcutaneous fat 
volume. Strikingly, while the presence of the 
rare allele predicted baseline values of muscle 
strength and fat volume, it did not predict 
significantly higher values of muscle hypertrophy 
or gained strength after resistance training. This 
suggests that the ability of muscle to hypertrophy 
and gain strength are controlled by genes other 
than CCL2 and CCR2.1,2
In addition to providing a research 
experience, our fellowships also presented the 
opportunity to observe patient care in the 
orthopaedic outpatient clinic and operating 
room. More over, we traveled to the International 
Conference on Children’s Bone Health in 
Montreal, Canada, to gain greater exposure to 
international research efforts in bone health. 
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… [I]ndividuals with the rare alleles 
consistently had the greatest baseline muscle 
strength and lowest subcutaneous fat volume. 
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Cloning and Expression of Human Adenovirus 
Precursor Protein VI and Mature Protein VI
There are 47 serotypes of the human adenovirus 
that are responsible for a group of respiratory 
diseases, including, but not limited to, 30 
percent of all colds, pneumonia and bronchitis, 
in addition to gastroenteritis, viral pink eye and 
cystitis.1 Epidemiological studies indicate an 
adenoviral agent as the cause of 5–10 percent of 
juvenile pneumonias and respiratory infections 
of children in North America.2 Respiratory 
infection with adenoviruses is also regularly 
responsible for a number of infant deaths and 
considerable morbidity among some adult 
populations. Serological prevalence studies 
suggest that the average individual undergoes 
a minimum of two or three clinical episodes 
of adenoviral infection during childhood.2 In 
addition, human adenovirus is one of the leading 
opportunistic infections that are a major cause 
of death in patients with Acquired Immune 
Deficiency Syndrome (AIDS) and deficient 
immune systems.3 
The human adenovirus proteinase (AVP) 
is required for the development of infectivity.4 
AVP is synthesized by the adenovirus and 
packaged into nascent virus particles. When 
activated, AVP cleaves virion precursor 
proteins, thereby rendering the virus particle 
infectious. AVP requires two viral cofactors for 
maximal activity — adenovirus DNA and an 
11-amino-acid peptide, known as pVIc, derived 
from the C-terminus of precursor protein VI 
(pVI). Protein VI also functions as a precursor 
“scaffolding” protein that plays a critical role 
in the assembly and maturation of the virus 
particle.5
The synthesis and investigation of the 
precursor and mature form of protein VI is 
essential because of its critical role in producing 
the pVIc cofactor required for proteinase 
activation and subsequent viral infection. To 
characterize the interactions of AVP and DNA 
that render the virus particle infectious, the 
genes for pVI and VI must be cloned, expressed 
in bacterial hosts and the resultant recombinant 
proteins purified. There is no evidence that pVI 
or VI has been successfully cloned or expressed 
prior to this experiment.
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This experiment established a novel, stepwise 
protocol for cloning pVI and VI genes and 
expressing the proteins in bacterial hosts. The 
genes for pVI and VI were successfully amplified 
from genomic adenovirus DNA, digested with 
restriction enzymes, ligated into prepared pET 
expression plasmids and transformed into 
bacterial hosts. PCR of the purified plasmids 
verified successful cloning of the correct gene 
sequences. Proteins pVI and VI were then 
expressed in BL21-codon plus(DE3)-RIPL cells 
grown in ZYM-5052 auto-inducing medium. A 
15 percent SDS-PAGE and an assay using AVP 
and Rhodamine fluorogenic substrate confirmed 
successful protein pVI and VI expression. 
A supply of purified recombinant proteins 
pVI and VI was produced, purified and stored 
for future research. The end 
products of this investigation 
will be significant in 
developing drug targets for 
anti-viral agents and providing 
information for the study of 
other viruses with congruent 
activation mechanisms. 
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binding of protein VI to hexon and the activation 
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The end products of this 
investigation will be significant 
in developing drug targets for 
anti-viral agents … .
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The Role of Retinoic Acid in Neuronal Phenotype Determination
An important element of the developing central 
nervous system is the acquisition of specific neu-
ronal phenotypes. Retinoic acid plays a funda-
mental role in CNS development and is essential 
for normal growth of the embryo. The effect 
of retinoic acid on neurotransmitter phenotype 
determination can be analyzed by examining the 
expression patterns of specific molecular markers.
The expression of a gamma-aminobutyric 
acid (GABA)ergic or glutamatergic neuron can 
be examined in a model vertebrate organism 
such as Xenopus laevis, the African clawed 
frog. GABAergic neurons release GABA, the 
most abundant inhibitory neurotransmitter in 
the CNS, and glutamatergic neurons release 
glutamate, the most abundant excitatory 
neurotransmitter in the CNS. In order to 
visualize the expression patterns, whole-
mount in situ hybridization was performed to 
examine the spatial 
expression of specific 
molecular markers 
during various 
stages of embryo 
development.1,2 The 
xGAT1 and xVGlut1 
RNA probes allowed 
visualization of the 
expression patterns 
of GABAergic 
and glutamatergic 
neurons, respectively. 
Normal expression 
of xGAT1 is first 
observed at late 
neurula stages in the 
anterior portion of 
the developing spinal cord.3 By tailbud stages, 
bilateral xGAT1 expression is apparent in all 
regions of the CNS, including distinct regions of 
the forebrain, midbrain, hindbrain and olfactory 
placodes.3
Normal expression of xVGlut1 is first 
detected at late neurula to early tailbud 
stage embryos with prominent expression in 
the developing trigeminal nerve and in the 
developing spinal cord.4 By later tailbud stages, 
xVGlut1 mRNA is observed in the pineal gland, 
the olfactory placodes and more posteriorly in 
the trigeminal and facial cranial nerves.4 
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It is believed that retinoic acid plays a fun-
damental role in the acquisition and patterning 
of GABAergic and glutamatergic phenotypes. 
Retinoic acid comes from the family of retin-
oids and has been correlated with causing birth 
defects in newborns, both when deficient and 
when present in excess. These include abnor-
malities in facial bone structure, in the ears and 
eyes, and in brain mass. Retinoic acid acts as a 
signaling molecule regulating critical processes 
during early development, including axial pat-
terning, cellular differentiation, tissue induction, 
proliferation and apoptosis.5 The natural concen-
tration of retinoic acid in the body is crucially 
important and is constantly regulated. 
In Xenopus development, retinoic acid 
becomes important at the beginning of gastrula-
tion (stage 10 of development two). This stage 
marks the point at which segregation of body 
layers begins to take place. It is known that 
excess concentrations of retinoic acid in the 
environment affect the formation of the neural 
tube. More specifically, the effect appears to be a 
truncated anterior of the CNS.
It is hypothesized that the expression patterns 
of the neurotransmitter markers will be altered 
by the presence of excess retinoic acid. To test 
this hypothesis, Xenopus embryos were exposed 
to various solutions of retinoic acid at different 
developmental stages.2 In situ hybridizations 
were conducted, with xGAT1 and xVGlut1 RNA 
probes. Whole mount examination revealed 
obvious malformation in the embryo. The effect 
on expression patterns of the molecular markers 
needs to be further analyzed via histological 
sections. More specific findings regarding the 
role of retinoic acid and its affects on expression 
patterns of GABAergic or glutamatergic neurons 
will help in understanding the acquisition of a 
specific neuronal fate. Furthermore, it will help 
in understanding the development of congenital 
birth defects in humans.
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A Potential Role for DHEA in Prostate Cancer
Dehydroepiandrosterone (DHEA) is the most 
abundant endogenous steroid produced by the 
adrenals of men and women, although levels 
decline markedly with age. DHEA is increas-
ingly consumed as a commercial nutritional 
supplement for its purported anti-aging effects, 
yet its usefulness, long-term safety and effects 
remain uncertain.1 
DHEA can be metabolized by the prostate 
gland and can increase expression of secondary 
mediators for epithelial growth and differen-
tiation. Furthermore, because it is a precursor 
to both estrogens and testosterone, contro-
versy exists as to whether DHEA enhances 
or reduces the risk of prostate cancer.2 Since 
supplements are not regulated by the Food and 
Drug Administration, The National Center 
for Complementary and Alternative Medicine 
(NCCAM) at the National Institutes of Health 
(NIH) plays a vital role in researching the effects 
of supplements such as DHEA. 
Prostate cancer is the second most common 
type of cancer among men in the United States, 
and approximately one out of three men will 
become afflicted.3 The prostate epithelium 
contains glandular cells that synthesize and 
secrete products of seminal plasma, including 
prostate-specific antigen (PSA), the major 
diagnostic marker for prostate cancer. These 
epithelial cells depend on androgenic stimula-
tion for their viability and secretory ability and 
become malignant during prostate cancer. They 
are surrounded by a fibromuscular stroma that 
not only physically supports the glands, but 
also contributes to the endocrine and paracrine 
microenvironments of these cancer cells. Thus, 
the stromal cells help control the growth and dif-
ferentiation of the epithelial cells, as well as play 
a critical role in mediating the responsiveness 
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of these cells to steroid hormones.4 My research 
aimed to determine what specific factors these 
stromal cells produced in response to DHEA and 
provide insight into how the stromal environ-
ment modulates conversion of healthy epithelial 
cells into malignant prostate cancer. 
Prostate epithelial cancer cells were co-
cultured with stromal cells and separated by a 
substance called Matrigel, which functioned like 
a permeable basement membrane, allowing the 
passage of soluble stromal mediators to the epi-
thelial cells. After the cells were grown, treated 
with DHEA and harvested, the co-cultured 
stromal RNA was extracted. Subsequently, 
cDNA was synthesized and real-time reverse 
transcriptase PCR was performed to measure 
expression of 84 genes related to human growth 
factors. 
Results from three separate experiments were 
comparable and showed the up-regulation of 
several specific genes, including FGF-1 (fibroblast 
growth factor), IGF-1 (insulin-like growth factor), 
FGF-7 (fibroblast growth factor) and HPRT-1 
(hypoxanthine phosphoribosyltransferase). While 
these results are preliminary, they may provide 
some insight into what growth factors the stromal 
cells produce in response to DHEA and can be 
further explored as targets for stromal regulation 
of epithelial cell function. My research experience 
only scratched the surface investigating the role 
of DHEA in prostate cancer, but I gained useful 
research experience and am optimistic about 
NCCAM’s future efforts on this important topic. 
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Middle Ear Epithelial Cell Secretion of Cytokines 
with Cigarette Smoke Condensate Exposure
Otitis media (OM), an inflammation of the 
middle ear, is a ubiquitous condition of early 
childhood accounting for 16 million physician 
office visits each year. OM is associated with 
hearing loss, delayed speech development and 
the potential for permanent middle ear damage. 
Environmental agents such as tobacco smoke 
have been shown to be a risk 
factor in the occurrence of OM 
in early childhood.1 OM can 
be classified by its associated 
clinical symptoms, otoscopic 
findings, complications and 
duration. There are two clas-
sifications of OM, acute and 
chronic, which differ in dura-
tion and result from different 
etiologies. Acute OM often 
results from upper respiratory 
infections; whereas chronic 
OM is usually non-infectious 
and thought to be due to 
chronic inflammation and 
mucous hyper-secretion. Environmental agents 
such as cigarette smoke are highly correlated 
with the occurrence of chronic OM. Studies 
conducted by different federal agencies suggest 
exposure to tobacco smoke may be a significant 
risk factor in the development of chronic OM in 
early childhood. The direct mechanism by which 
cigarette smoke exposure results in OM remains 
under investigation. 
The etiology of OM inflammation within 
the middle ear mucosa is primarily initiated, 
mediated and regulated by pro-inflammatory 
cytokines: TNF-α, IL-1β, IL-6 and IL-8.2 The 
inflammatory cascade is initiated by micro-
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organisms and/or their products, leading to 
an increase in restrictive oxygen species (ROS) 
and causing activation of the NF-κB complex. 
NF-κB translocates to the nucleus and tran-
scribes genes encoding for ICAM-1, TNF-α, 
IL-1β and several secondary pro-inflammatory 
cytokines.
Cigarette smoke induces pro-inflammatory 
cytokines in the lower respiratory system, and 
exposure of cigarette smoke to the rat lung 
induces redox-sensitive transcription factors 
NF-κB and AP-1, which are linked to the 
transcription of specific inflammatory cytokines 
and chemokines.3 Cigarette smoke also induces 
the synthesis of glutathione and gamma-
glutamylcysteine that is associated with AP-1 or 
an AP-1 like response element.3 In addition to 
increasing transcription of inflammatory genes, 
cigarette smoke also decreases HDAC2 activity 
in the rat lung, in turn decreasing histone 
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deacetylation, and thus increasing transcription 
of pro-inflammatory genes. 
We hypothesized that cigarette smoke 
condensate (CSC) stimulation would activate 
NF-κB and ultimately increase pro-inflammatory 
cytokine secretion in mouse middle ear epithe-
lium cells (mMEEC). 
To investigate our hypothesis, we used a 
mouse inflammatory antibody array to measure 
40 different pro-inflammatory cytokines from 
CSC stimulated mMEEC. The mMEEC was 
stimulated with 0 micrograms per microliter, 20 
micrograms per microliter and 40 micrograms 
per microliter CSC for two, eight and 24 hours, 
respectively. The inflammatory antibody array 
was analyzed with chemiluminescence imaging. 
We observed a significant increase in pro-inflam-
matory cytokines IL-6, TNF-α, IFN-γ, IL-4 and 
IL-13. We plan to further analyze these cytokines 
of interest using Enzyme Linked Immunosorbent 
Assay (ELISA) kits to confirm our findings. 
In conclusion, CSC activated pro-inflam-
matory cytokine secretion in mMEEC in vitro. 
These findings will bring us closer to under-
standing the biological mechanism responsible for 
the high correlation of OM with young children 
exposed to second-hand smoke. 
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Development of an In Vitro Model
of Respiratory Tract Submucosal Glands
A mucosal layer protects the respiratory tract 
epithelium against pathogens and environmental 
toxins. Mucin glycoproteins (mucins) are 
overproduced in chronic diseases of the 
respiratory tract, such as cystic fibrosis (CF) and 
chronic rhinosinusitis 
(CRS), and contribute 
significantly to disease 
morbidity and mortality.1 
Mucous hypersecretion 
predominantly 
results from goblet 
cell hyperplasia and/
or submucosal gland (SMG) hyperplasia. In 
vivo and in vitro model systems are used to 
investigate mechanisms of mucin hypersecretion 
in the conducting respiratory tract epithelium. 
However, there is no established in vitro 
glandular model for the submucosa.
Presently, the standard in vitro models consist 
of differentiated primary human bronchial 
epithelial (HBE) or nasal epithelial cells grown 
on transwell plates coated with collagen at an 
air-liquid interface. Within two weeks, these 
cells differentiate into a conducting respiratory 
tract epithelium with cilia, basal and goblet 
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cells.2,3 The models secrete both MUC5AC 
and MUC5B mucins, which are in vivo 
markers for goblet cells and submucosal glands, 
respectively.4 However, these cell models do 
not develop glands, although they are clearly 
pluripotent and express 
glandular proteins. We 
hypothesized that HBE 
cells would develop 
glands if grown in the 
appropriate context. 
Submucosal glands 
are invaginations of 
the epithelium and are composed of ductal and 
secretory cells (both mucous and serous) that 
secrete mucins and host defense proteins into 
the mucosal layer. Cells from various tissues 
have already been shown to develop intestinal, 
mammary, salivary, pancreatic or oviduct glands 
when grown on Matrigel, a basement membrane 
complex isolated from murine tumors.5,6 The 
main component of Matrigel is laminin, as 
well as collagen type IV, heparan sulfate and 
SUBMUCOSAL GLANDS MODEL 
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FIGURE 1: Microscopic view 
of gland-like structure formed 
by H-Tert immortalized tracheal 
bronchial epithelial cells when 
grown mixed with Matrigel on 
Day  9 after plating. 
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proteoglycans. At 37° C, Matrigel forms a three-
dimensional gel that supports cell morphogenesis 
and differentiation.7 Currently, there are no 
reports of respiratory tract gland (submucosal 
gland) development using Matrigel. 
Two different approaches were used: 
respiratory tract-derived cells were either 
grown on top of, or mixed with, Matrigel. 
Cell media was changed as required and cells 
were periodically monitored by microscopy. 
Experiments were carried out using three 
different cell lines, including Calu-3 cells (cancer 
cell lines of SMG origin), H-Tert immortalized 
tracheal bronchial epithelial cells and normal 
human bronchial epithelial (HBE) cells. 
Our preliminary results showed that 
respiratory tract-derived cells formed glandular-
like structures but did not differentiate further 
after five days. A literature review indicates that 
epithelial cells from various tissues require seven 
to 15 days of growth on Matrigel to differentiate 
into glands, with subsequent apoptosis to form 
a glandular lumen.7,8 Our data indicated that 
under these conditions, respiratory tract cells do 
not undergo apoptosis to form a lumen. Future 
experiments will focus on inducing apoptosis 
in order to facilitate differentiation of SMG 
and thus establishment of an in vitro model to 
investigate SMG development and hyperplasia in 
respiratory diseases such as CRS and CF. 
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A Three-Dimensional Model of Epicardial Development
Development of the epicardium is critical to 
proper heart formation. The epicardium provides 
all of the precursor cells that form the coronary 
system and supplies signals that stimulate cardiac 
myocyte proliferation. The epicardium forms 
from mesothelial cells (proepicardial [PE] cells) 
associated with the developing liver. Here, a 
model of epicardial development is presented. PE 
cells have been isolated from chicken embryos 
and cultured on a 3-D scaffold. This 3-D model 
system consists of a tubular scaffold engineered 
from type-I collagen and optimized to support 
the growth of embryonic cardiac tissues.1,2,3
Using scanning electron microscopy (SEM), 
we compared in vivo PEs with PEs cultured on 
the tube scaffold for three days. In vivo PE cells 
appeared as cobblestone cells covering the AV 
sulcus of HH stage-17 chicken hearts as well as 
the outflow tract of the heart. Cells on the tube 
also were observed to migrate as a sheet and 
possessed apical villi characteristic of in vivo 
PE cells.4 Similarly, 
PE cells cultured 
on the tube scaffold 
displayed a cobblestone 
morphology and 
possess apical villi.5 
SEM data also revealed 
PE cells could migrate 
in a sheet-like fashion 
and inhabit pit-like 
areas of the tube 
scaffold.5 Moreover, 
PE cells cultured on 
the collagen scaffold 
clearly maintained 
their morphological 
characteristics and 
closely resembled their 
in vivo counterparts. 
Cultured PE cells also 
expressed markers for 
both endothelial and 
smooth muscle cells, 
bearing a striking 
resemblance to in vivo 
cells undergoing 
vasculogenic 
processes.5 Taken 
together, these data 
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support the tube scaffold as a viable model for 
epicardial development. 
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FIGURE 1: COMPARATIVE 
MORPHOGENESIS OF THE 
PROEPICARDIAL CELLS. A, B, 
C, E, G: Representative proepicardium (PE) 
morphogenesis in the stage-17 chicken embryo. 
A: Stage-17 chicken embryo showing the 
branchial arches (BA), heart tube (HT) and the 
proepicardium (PE). B: Higher magnification 
of (A) showing the PE extending from the 
liver toward the heart tube (HT). C: PE cells 
migrate as a sheet from the atrioventricular 
sulcus toward the outflow tract. The dashed 
line indicates the boundary of migrating cells. 
D, F, H: Representative images of PE cell 
morphogenesis on the tubular scaffold.  
D: Chicken PE cells cultured on the collagen tube 
exhibit a cobblestone appearance. The dashed 
line identifies the boundary of migrating PE cells 
on the collagen tube. E: Higher magnification 
of (C) shows that the in vivo cells migrate as a 
sheet over the HH stage-18 chicken heart.  
F: PE cells exhibit a cobblestone morphology and 
are found in pit-like areas of the tube scaffold. 
G, H: Arrows show the presence of apical villi 
on the surface of PE cells in vivo and on the 
collagen scaffold in G and H, respectively (scale 
bars equal 100 μm in A-C and 10 μm in D-H).
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Improving MRI Detection of Creutzfeldt-Jakob Disease
Creutzfeldt-Jakob 
disease (CJD) is a rare 
neurodegenerative 
prion disease charac-
terized by the accu-
mulation of abnormal 
prion protein leading 
to neuron loss, vacu-
olation and/or astro-
gliosis. CJD is charac-
terized by rapid-onset 
dementia, rapid degen-
eration and death. In 
this study, Libyan-born 
Israelis at increased 
risk for the inherited form of CJD were examined 
at Sheba Medical Center (Tel Hashomer, Israel). 
The patients suffered from either familial or spo-
radic CJD. Our group previously reported similar 
radiological findings for familial cases when com-
pared to the more common sporadic form.1
This study analyzed two diffusion-weighted 
(DWI-MRI) sequences to evaluate the sensitivity 
of higher b-value DWI (b=2000 s/mm2), as 
compared with the more common lower b-value 
sequence (b=1000 s/mm2). DWI-MRI measures 
differences in proton movement indicative of 
tissue structure, and it has been demonstrated to 
be an early marker of CJD-related pathology with 
better sensitivity and specificity than other CJD 
criteria such as the cerebrospinal fluid 14-3-3 
protein detection and EEG patterns.2 DWI-MRI 
patterns in CJD patients typically include hyper-
intensities within the caudate nucleus, putamen, 
thalamus and cortical ribbon; these findings 
putatively correspond to vacuole formation, the 
hallmark histological finding of prion diseases.3
B-value is a function of diffusion gradient 
strength; a higher b-value is thought to be more 
sensitive to diffusion and has been used with suc-
cess in detecting other diseases.4 A high b-value 
DWI may provide earlier detection of CJD 
pathogenesis and improve understanding of the 
progression of imaging changes.
DWI scans of 10 patients and age- and 
gender-matched controls were analyzed using 
 clinical practice. . .
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Comparisons were examined using Apparent 
Diffusion Coefficient (ADC) maps, a quantitative 
measure of proton diffusion capable of providing 
more robust statistical comparison. The compar-
ison of control subjects to CJD patients showed 
greater sensitivity to basal ganglia and thalamic 
changes using high-value sequences, while the 
lower b-value detected more cortical changes. 
These findings suggest greater diffusion-weighted 
MRI sequences may be advantageous in detecting 
CJD-related changes. 
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FIGURE 1: DIFFUSION COEFFICIENT (ADC) MAPS OF PATIENTS WITH CJD. 
Comparing ADC maps of patients with controls showed more significant reductions in ADC within the thalamus 
and striatum using b=2000, suggesting greater sensitivity with high b-value (right).
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Retinoblastoma is an intraocular malignancy 
that occurs in children when a germline 
mutation of RB1 is inherited and a somatic 
mutation inactivates the second RB1 allele.1 
Common modes of treatment to preserve vision 
include triple-drug chemotherapy, radiation, 
laser and cryotherapy. When chemotherapy 
is combined with focal treatments, up to 
40 percent of patients do not respond and 
enucleation of the eye may be required to prevent 
metastatic retinoblastoma which is often fatal.2 
Current drugs have undesirable side effects, 
including an increased risk of developing acute 
myeloblastic leukemia or hearing loss from 
ototoxicity.2,3 Since retinoblastoma is a rare 
disease (300 new cases in the United States each 
year), preclinical animal models that recapitulate 
the tumorgenicity are important for developing 
new chemotherapy treatments.4 
The tumor suppressor RB1 gene is 
responsible for regulating cell proliferation, while 
the p53 gene regulates cell response to stresses 
such as DNA damage by inducing apoptosis.5 
In retinoblastoma, because the p53 gene is 
intact yet suppressed, it is a prime target for 
up-regulation to promote apoptosis and stop 
clonal expansion in tumors. The purpose of 
this research is to develop more effective, less 
toxic novel chemotherapeutic treatments using 
small molecules that up-regulate p53 to induce 
apoptosis in p53-suppressed retinoblastoma cells. 
By identifying compounds in a National Cancer 
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Institute library that were previously shown 
to induce p53 in other types of cancer cells, 
we screened and selected small molecules that 
demonstrated cytotoxic effects in retinoblastoma 
cells. 
One such p53 activator investigated was 
a small molecule that “Reactivates p53 and 
Induces Tumor cell Apoptosis” (RITA). In 
previous studies, RITA was shown to suppress 
the growth of osteosarcoma and fibro-sarcoma 
cells.6 By analyzing the effects of RITA in RB1 
tumor growth assays, RITA demonstrated potent 
cytotoxic effects. We calculated the 50 percent 
growth inhibitory 
concentration 
(GI50) from in vitro 
experiments, and 
correlated growth 
inhibition with Western 
Blot analyses. This 
data demonstrates 
suppression of cell 
proliferation while 
up-regulating p53 gene 
expression.
To recapitulate 
the tumorgenicity 
properties of RB1 
in animals, we used 
an ocular xenograft 
rat model. Human retinoblastoma cells were 
transplanted directly into the eyes of newborn 
rat pups to establish tumor growth. Using a 
microscope and the tip of an insulin syringe, 
the eyelids of anesthetized rat pups were 
surgically opened and the posterior chamber 
was infused with cultured cells. Tumor growth 
was established over 14 days and the rats were 
treated with drug and a control vehicle. MS-275 
is a histone deacetylase inhibitor and known 
anti-tumor compound previously proven to 
suppress retinoblastoma cell growth in vitro. The 
rats were treated with either MS-275 or vehicle 
every other day for 12 days and were imaged 
using a Luciferin assay every other day. Our 
results indicate statistically significant inhibition 
of tumor growth with MS-275 treatment when 
MS-275 IN OCULAR XENOGRAFT MODEL
 
FIGURE 1: Y79-LUC CELLS WERE TRANSPLANTED INTO THE 
VITREOUS OF DAY-OLD RATS. On day-14 post-transplant the animals were treated 
by intraperitoneal injection of 20 mg/kg MS-275 or vehicle for 12 days (six treatments total) and 
injected with 150 mg/mL D-Luciferin for imaging with the IVIS Lumina imaging system.
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compared to control animals (Figure 1). At the 
end of the treatment period, MS-275 treated 
animals had 62 percent tumor growth inhibition 
when compared to vehicle-only control animals 
(p = 0.038).
Through the analysis of 140,000 compounds 
in the NCI library for small molecules that are 
good candidates for in vitro and ocular xenograft 
model experimentation, we plan to identify novel 
antitumor chemotherapies for the treatment of 
retinoblastoma.
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Surgical Correction of Spinal Deformities after Heart 
Transplantation: A Case Series Report
Several studies have documented an association 
between congenital heart disease and scoliosis 
in children.1-4 More recent research has shown 
that children undergoing any type of solid 
organ transplantation are placed at increased 
risk for developing a potentially limiting 
spinal curvature.5 Among all solid organ 
transplantations, 
heart 
transplantation 
has been reported 
to be a major 
risk factor for the 
development of 
spinal deformity.5 Armed with this knowledge, 
the pediatric orthopaedic research team at 
Morgan Stanley Children’s Hospital of New 
York-Presbyterian Hospital reviewed the cases 
of patients undergoing scoliosis correction after 
orthotopic heart transplantation to establish any 
necessary changes in their perioperative care to 
ensure good surgical results. 
This study was a retrospective case series 
report of six heart transplant recipients with a 
diagnosis of scoliosis, requiring corrective spinal 
surgery between 1995 and 2007. The causative 
factor necessitating heart transplantation varied 
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among the patient population. Two patients had 
congenital heart disease, two had congenital 
cardiomyopathy and one had Marfan syndrome. 
Hospital charts were reviewed to obtain clinical 
information regarding the heart transplantation, 
the spinal procedure and the patient’s status 
(both cardiac and spinal) at the time of 
scoliosis correction. Diagnostic test results, 
including preoperative cardiac catheterizations, 
echocardiograms and preoperative Cobb 
angles, were obtained from the surgeon’s notes. 
Intraoperative and follow-up information 
also was reviewed. Three different procedures 
were used to correct the scoliosis in the heart 
transplant patients. Four patients underwent 
a posterior spinal fusion and instrumentation, 
one patient underwent a posterior segmental 
instrumentation without fusion (growing rods), 
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in children and adolescents who have undergone heart 
transplantation.
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and the last patient received an anterior release 
and posterior fusion with instrumentation. 
The average age at time of heart 
transplantation was 7.8 ± 4.5 years. The children 
then underwent surgical correction for their 
scoliosis at a mean age of 13.3 ± 5.6 years. 
Average length of follow up after the scoliosis 
surgery was 21.5 ± 14.7 months. Two of the 
patients in the cohort died as a result of their 
cardiac condition. Three patients had 
complications following the scoliosis 
procedure. These complications included 
a fractured single rod construct in one 
patient, device migration after initial 
surgery in another patient and one 
instance of wound infection. None of 
the complications resulted in adverse 
sequelae. Appropriate curve correction 
and control was achieved for all six 
patients. The mean preoperative major 
curve was 70.2°. At the time of last 
follow up, the spinal curvature had 
corrected to a mean curve of 22.6° 
(p<0.10).
This case report demonstrates 
how spinal deformity surgery can be 
successfully performed in children 
and adolescents who have undergone 
heart transplantation. Especially 
with immunosuppressive therapy 
and numerous comorbid conditions, 
these patients represent an especially 
challenging cohort. Adequate 
surgical correction without serious 
adverse conditions, therefore, is 
best accomplished with meticulous 
preoperative planning and extensive 
multidisciplinary cooperation both 
intraoperatively and postoperatively. 
Despite the risks and challenges, 
correction of spinal deformity in 
pediatric heart transplant patients can 
significantly improve quality of life.
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FIGURE 1: 
POSTOPERATIVE 
LATERAL X-RAY OF 
A STUDY PATIENT. 
Note the posterior spinal 
instrumentation inserted during 
the scoliosis surgery as well 
as the anterior staples used to 
fuse the sternum following the 
heart transplantation.
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Hip Arthroscopy and the Treatment of Femoroacetabular 
Impingement
This project aimed to assess the long-term 
prognosis for patients who presented with femo-
roacetabular impingement (FAI) and underwent 
subsequent hip arthroscopy. FAI occurs when 
the femoral head does not have its full range of 
motion within the pelvic acetabulum. FAI is 
increasingly recognized as a cause of osteoarthritis 
in the hip through dete-
rioration of the labrum 
and articular surface. 
Impingement itself is the 
premature and improper 
collision between the 
head and/or neck of 
the femur and the 
acetabulum. This causes 
a painful and decreased 
range of hip joint 
motion. FAI commonly 
presents as “cam-type” 
impingement, a result 
of excess bone forming 
around the head and/
or neck of the femur; 
“pincer-type” impinge-
ment, an overgrowth of 
the acetabular rim; or a resulting FAI where the 
acetabulum is angled in such a way that abnormal 
impact occurs between the femur and the rim of 
the acetabulum.1
When the excess bone present on the femoral 
head and/or neck abuts the rim of the acetab-
ulum, the cartilage and labrum that line and 
cushion the acetabulum can be damaged. The 
extra bone can appear on X-rays as a small protru-
sion. When the protrusion repeatedly rubs against 
the cartilage and labrum, such as in athletes who 
perform repeated leg flexion and extension, the 
cartilage and labrum eventually may tear, causing 
pain. As more tissue tears, the femoral bone will 
impact with pelvic bone resulting in arthritis. 
Tears of the labrum can also fold into the joint 
space, causing a further painful restriction of hip 
motion.2,3
Arthroscopy of the hip has become an 
accepted surgical procedure with well-defined 
indications and expected outcomes, primarily 
due to recent advances in surgical instrumen-
tation and techniques.3 Hip arthroscopy is 
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performed as an outpatient procedure using fluo-
roscopy for instrument placement. The proce-
dure has been slower to evolve than arthroscopy 
of other joints because the hip is much deeper 
in the body. Furthermore, because the hip is a 
“ball-and-socket” joint, it is necessary to employ 
traction to expose the joint enough to fit the sur-
gical instruments inside 
without causing further 
tissue damage. The basic 
principle of surgical 
treatment of FAI is to 
restore sphericity to the 
femoral head, thereby 
relieving the impinge-
ment. The surgery also 
aims to address the 
pathological changes in 
the labrum and articular 
cartilage.1
Studies have shown 
that the vast majority of 
hip arthroscopy patients 
return to sports and 
other physical activities 
at their peak level of 
performance prior to the onset of hip pain. The 
majority of patients clearly get better, but it is not 
yet clear to what extent the procedure stops the 
course of arthritis. Patients who have underlying 
skeletal deformities or degenerative condi-
tions may not experience as much relief from 
the procedure as would a patient with simple 
impingement.
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FIGURE 1: BALL-AND-SOCKET JOINT. A) Normal 
hip; B) Cam impingement; C) Pincer impingement; D) Combination 
of cam and pincer impingement.
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Novel “Non-Fusion” Technologies May Help  
Patients with Spinal Stenosis
Technological advances, especially spanning 
the last two decades, have greatly advanced the 
field of spinal surgery. Many of these advances 
focused on creating alternatives to spinal fusion. 
Historically, spinal fusion has been widely 
used to treat degenerative pathologies in the 
spine. However, eliminating vertebral motion 
and placing greater stress on adjacent spinal 
segments limits the effectiveness of these fusions. 
As a result, new classes of non-fusion surgical 
devices have emerged, including interspinous 
spacers, facet replacement systems and posterior 
dynamic stabilization systems. These devices 
offer innovative, as well as minimally invasive, 
approaches to spinal surgery. The interspinous 
spacer, facet replacement system and posterior 
dynamic stabilization are each indicated to treat 
spinal stenosis.1,2 
This retrospective study evaluated the 
percentage of patients who would be eligible 
to receive one of these 
non-fusion devices. 
Eligibility was defined 
as matching at least one 
indication but none of the 
contraindications for each 
device. There have been no 
published studies investigating the percentage of 
patients who may potentially benefit from any of 
these devices.
Patients were divided in two groups, the first 
including patients who had a lumbar fusion 
and the second consisting of patients who had 
any other lumbar surgery. Indications and 
contraindications in this study were adapted 
from IDE clinical trials for interspinous spacers, 
facet replacement and posterior dynamic 
stabilization. We evaluated the inclusion/
exclusion criteria for multiple models in each 
category and selected the most stringent criteria. 
As a result, indications and contraindications 
were based on the inclusion/exclusion criteria 
for the IDE clinical trials of X Stop interspinous 
spacer, Anatomic Facet Replacement System and 
Stabilimax posterior dynamic stabilization.
Medical records of 100 patients who had 
lumbar fusions were cross-referenced with 
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indications and contraindications for each 
device. Of these patients, 22 percent were eligible 
to receive an interspinous spacer, 30 percent 
were eligible to undergo facet replacement and 
34 percent were eligible to receive posterior 
dynamic stabilization. Twenty-three percent of 
patients were eligible to receive all three devices, 
while 65 percent were not eligible to receive 
any device. Reviewing 100 patients who had a 
lumbar surgery other than fusion, 25 percent of 
patients were eligible to receive an interspinous 
spacer, 26 percent were eligible to undergo facet 
replacement and 27 percent were eligible to 
receive posterior dynamic stabilization. Twenty-
five percent of patients were eligible to receive all 
three devices and 73 percent were not eligible to 
receive any of the devices.
Interspinous spacers, facet replacement and 
posterior dynamic stabilization, therefore, stand 
to impact 20–30 percent of lumbar surgeries. 
As future research and technology expand the 
indications or eliminate the contraindications for 
these devices, the number of patients eligible to 
receive these devices may increase significantly. 
We predict that these devices will have a 
significant impact on spine surgery.
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the contraindications for these devices, the number of patients eligible to 
receive these devices may increase significantly. 
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Effect of Bone Density on Mechanical Properties after 
Percutaneous Vertebroplasty
Vertebral compression fractures are the most 
common injuries resulting from osteoporosis, 
with an estimated incidence of 700,000 per year 
in the United States.1 Among persons over 65, 
33 percent of women have sustained a vertebral 
compression fracture, and this fracture rate is 
three times higher in women than in men. These 
fractures cause acute and chronic back pain, 
disability and increased mortality risk.2 One 
treatment option is percutaneous vertebroplasty 
or injection of cement, typically polymethyl 
methacrylate (PMMA) acrylic bone cement, into 
the vertebral body. However, previous studies 
have shown that injecting an excessive amount 
of cement can increase the risk of both cement 
leakage and secondary adjacent fractures.2 While 
the primary purpose of the surgery is to eliminate 
back pain, patients and practitioners expect other 
benefits, including mechanical reinforcement 
of the vertebra as well the prevention of adverse 
effects.
The primary objective of this study was to 
determine how bone mineral density (BMD) 
affects mechanical stiffness and strength of the 
vertebral body after vertebroplasty. A secondary 
objective was to determine how the relation-
ships between mechanical properties and BMD 
vary with the amount of cement injected. The 
clinical goal of this research was to help physi-
cians understand how BMD can identify a dose 
of cement that can restore mechanical properties 
to the greatest extent possible for a specific patient 
without increasing the risk of complications.
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Bone mineral density of 13 vertebral columns 
from adult Caucasian female cadavers was mea-
sured with a dual-energy X-ray absorptiometry 
(DEXA) scanner. Vertebral bodies (n=126) were 
assigned to five groups based on cement treat-
ment: intact, untreated, 4 percent fill, 12 percent 
fill and 24 percent fill. Non-intact specimens 
were compressed asymmetrically to simulate a 
wedge compression fracture before treatment 
with PMMA cement. Strength and stiffness were 
measured in axial compression. 
The two most significant findings of the 
study suggest that: (1) the improvements in 
stiffness and strength resulting from vertebro-
plasty depend significantly on bone density, and 
(2) only the highest cement dose in the study 
(24 percent vertebral body fill, average of 7 mL) 
had an appreciable effect on either mechanical 
property. Regarding strength, only the 24 per-
cent fill group improved strength over untreated 
levels, and greater improvements in strength 
were seen in patients with higher bone density. 
Unlike stiffness, however, the strength of the 24 
percent fill group not only improved relative to 
the untreated group but was enhanced beyond 
the intact levels. The greatest improvements 
in stiffness would be expected in patients with 
higher bone density (who are the least likely to 
suffer a fracture or need vertebroplasty). Results 
suggest that highly osteoporotic patients may 
receive the least amount of improvement in 
FIGURE 1: X-RAYS 
VERIFYING CONSISTENT 
VERTEBROPLASTY. 
All cement was injected using a 
transpedicular approach through 
the left pedicle with the needle tip 
in the anterior third of the vertebral 
body near the axial midplane. (A) 
L3 vertebra injected with 4 percent 
volume of cement. (B) T12 vertebra 
injected with 12 percent volume of 
cement. (C) L2 vertebra injected with 
24 percent volume of cement.
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mechanical properties from vertebroplasty. For 
these patients, it may be advisable for clinicians 
to limit their expectations of vertebroplasty to 
pain relief but not mechanical benefit and to 
select a cement volume that will minimize risks 
of adverse events. 
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Identifying the Correlation between Pseudo-bulbar  
and Cognitive Impairment in Primary Lateral Sclerosis
Primary Lateral Sclerosis (PLS) and Amyotrophic 
Lateral Sclerosis (ALS) both involve degenera-
tion of neurons. In PLS, loss of corticospinal 
tract Upper Motor Neurons (UMN) results in 
stiffness and brisk reflexes. In ALS, there is loss 
of UMN and Lower Motor Neurons (LMN); 
as a result, one finds atrophy, fasciculation 
and diminished reflexes in addition to UMN 
findings. 
Although Pringle et al have developed a clas-
sification scheme for PLS, there still remains a 
question as to whether PLS and ALS are indeed 
separate disease entities.1 A previous study found 
that stiffness and spasticity are more commonly 
seen at the initial presentation of PLS and that 
wasting of the limb is rare, and concluded, “a 
patient presenting with spasticity who does not 
develop wasting within three years most likely 
has PLS.”2
ALS patients often manifest cognitive 
changes of frontal lobe executive dysfunction to 
varying degrees, in some cases leading to fronto-
temporal dementia (FTD). These impairments 
are most commonly seen in those ALS patients 
with bulbar impairment. Schreiber et al found, 
“there is a fronto-temporal pattern of cognitive 
dysfunction in ALS expressing itself early in the 
course of the disease and mainly with bulbar 
forms.”3 Furthermore, Lomen-Hoerth found in 
her study that half of patients showed executive 
function deficits.4 
To further elucidate whether there is a dis-
tinction between ALS and PLS, our study aimed 
to determine if a correlation exists between 
bulbar dysfunction and cognitive impairment 
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in the PLS population. Fifteen PLS patients and 
six age-matched, healthy volunteers participated 
in the study. The full battery of bulbar function 
measures were carried out on 14 of the patients 
and two of the volunteers. This work up included 
clinical examination measures for hyperreflexia 
in addition to two speech measures: the rate of 
speech and the Assessment of Intelligibility of 
Dysarthric Speech test. The measures of the rate 
of speech and clarity of enunciation declined in 
parallel; as speech became slower it also became 
more difficult to understand. Rate of speech 
also reflected the presence of hyperreflexia; brisk 
jaw jerks and gag reflex were associated with 
slow rates of speech as well. The rate of speech 
was thereafter used as the primary measure of 
bulbar function for comparison with the Mattis 
DRS-2 dementia score. The psychologist in our 
group obtained the dementia scores for 14 of the 
patients and six of the volunteers.
Preliminary analysis of the correlation 
between rate of speech and scores on the Mattis 
dementia scale does not suggest a correlation at 
this time. Regression analysis with a straight line 
fit was performed in an attempt to elucidate this 
relationship. We concluded that the relationship 
between cognitive function and bulbar dysfunc-
tion should be studied in a larger population of 
patients with PLS and compared to patients with 
ALS to better understand the common features 
of these disorders. Furthermore, understanding 
the underlying cortical pathology by imaging 
measures of atrophy as well as pathologic studies 
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in PLS may further help explain the disease pro-
cess itself. 
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Clopidogrel in a Pediatric Population: Safety and Efficacy  
Results from a Single Center
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Although thrombotic diseases are less prevalent 
in children than in adults, complex pediatric 
patients, such as those with congenital heart dis-
ease, remain at risk for clot formation. Few guide-
lines exist for treatment of pediatric patients, 
leading pediatric practitioners to prescribe 
drugs, such as clopidogrel, off-label based upon 
extrapolation from adult experience and perceived 
clinical need. 
Evidence-based information on clopidogrel, a 
thienopyridine derivative and potent antiplatelet, 
is limited to adults at risk for, or with a history 
of, ischemic stroke, acute coronary syndrome, 
peripheral arterial disease or are at risk of death 
from vascular disease.1 Several large, randomized 
trials have evaluated the safety and efficacy of 
clopidogrel in adults using pre-determined dosing 
criteria, and generally found the drug to be safe 
and efficacious.2,3,4 
Published material supporting the safety and 
efficacy of off-label use of clopidogrel in the pedi-
atric population remains scarce. Several pediatric 
studies of clopidogrel performed outside of the 
United States are underpowered by small sample 
sizes. Two such studies performed at the Hospital 
for Sick Children in Toronto, Canada had cohorts 
of only 15–17 patients. Overall, both studies 
found clopidogrel to be well tolerated in children 
with minimal adverse events, the majority due to 
minor bleeding.5,6 
We performed a study to provide descriptive 
information about off-label treatment practice 
with clopidogrel in a larger pediatric popula-
tion. Patients (≤ 18 years) who were prescribed 
clopidogrel between March 2002 and August 
2005 were retrospectively identified at Children’s 
Hospital, Boston, MA. Data from the time of 
the first documented clopidogrel use to the most 
recent follow-up were collected and adverse events 
were classified according to seriousness and rela-
tionship to clopidogrel. 
Among 90 patients, 53 percent were male, the 
median age was 6.7 years and the median weight 
was 23.6 kg at first clopidogrel use. Prescriptions 
were mostly for cardiac indications (96 percent) 
with the remainder for neurological indica-
tions (4 percent). Common cardiac indications 
included history of thrombosis involving a con-
duit or shunt, abnormal vasculature with poten-
tial for low flow and device placement. Median 
total dose was 1.3 mg/kg/day and duration of 
therapy varied greatly (median 45 days, < one 
day – four years). Minor bleeding occurred in 
three patients, all on concomitant acetylsalicylic 
acid (ASA). One patient experienced catastrophic 
bleeding after a vessel tear during catheteriza-
tion. Another patient with poor ventricular 
function and a fenestrated Fontan (an operation 
performed on children with complex congenital 
heart defects) had baffle thrombosis and subse-
quent stroke while on clopidogrel and ASA. 
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In conclusion, our study demonstrated that 
clopidogrel prescribed for children of all ages 
was well tolerated. Most prescriptions were for 
thrombosis prevention in patients with cardiac 
disease. Bruising and minor bleeding events 
occurred rarely. While various trials demonstrate 
the benefits of treatment with clopidogrel to pre-
vent thrombotic events in adults, a need remains 
for further clinical trials examining the safety and 
efficacy of clopidogrel in children.2,3,4 A qualita-
tive prospective study would provide additional 
information about the burden of drug use on 
families, and could capture additional informa-
tion about dosing, safety and efficacy that can 
improve the application of this drug in children. 
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Development of Class I HLA Typing Assay for HIV  
Clinical Trials in East Africa
Highly polymorphic human leukocyte antigen 
(HLA) class I and II genes are important host 
genetic factors whose encoded molecules form 
intracellular complexes with pathogen-derived 
peptides and migrate to surfaces of infected cells 
and mediate adaptive immune responses. This 
process is fundamental to HIV infection and 
AIDS progression. While many relationships 
between HLA genotypes and HIV/AIDS are 
well established, scientists emphasize the need 
to study the influence of HLA alleles on the 
efficacy of HIV drugs.1,2,3 This need is apparent 
in the development of a global HIV vaccine that 
targets the diverse populations of Sub-Saharan 
Africa, where an estimated 25 million people are 
infected with HIV.4
These HIV vaccine clinical trial participants 
are ideal candidates for studying HLA 
genotypes. Subsequent identification of these 
genotypes can in turn be used to interpret 
drug efficacy in participants.1,5 “HLA typing” 
describes methods used to identify HLA alleles 
based on HLA gene sequences. Techniques 
usually involve conventional polymerase 
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chain reactions (PCR) which incorporate 
sequence-specific primers (SSP), sequence 
specific oligonucleotide probes (SSOP/SSO) or 
sequence-based typing (SBT).6 Real time PCR 
uses primer-probe combinations to distinguish 
HLA alleles based on fluorescence emissions 
and melting curve profiles, which are cheaper 
than SBT and do not require loading agarose 
gels which are prone to contamination. Many 
real-time PCR systems also use 384-well reaction 
plates, which produce large amounts of data in a 
short period of time. Such advantages have made 
it a popular method of HLA typing.7 
I was part of a team developing an SSP-
real time PCR assay for HLA class I typing to 
support ongoing HIV vaccine clinical trials in 
East Africa. During my time there, we developed 
an assay capable of distinguishing among 14 
alleles of the HLA-A locus of HLA class I known 
to be predominant in 80–90 percent of East 
African populations. The completed system, 
which also will type the remaining HLA-B and 
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HLA-C loci of HLA class I, will perform HLA 
class I typing for four individuals in less than 
two hours at a third the cost of SBT. Through 
such efficiency, our assay also can be performed 
in East African clinical trial field labs where 
other laboratory tests are performed at low costs.
Besides studying the efficacy of drugs in these 
settings, HLA genotyping data generated by our 
assay can be combined with HIV sequencing 
and epidemiological data from patients — 
using bioinformatics tools — to study the 
emerging selective pressures created by the AIDS 
epidemic.8 Such premises were behind recently 
demonstrated “HLA footprints,” which show 
how HIV viruses mutate and escape immunity 
in response to particular HLA types within a 
population.9 This is just another suggestion for 
how large-scale HLA genotyping data can be 
used effectively. 
Overall, through its ability to support the 
large-scale and cost-effective HLA genotyping 
needed for studying the efficacy of HIV vaccine 
candidates in East African clinical trials, this 
assay could be an important component in the 
design of a global HIV vaccine.
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Gastric Stimulation for Vomiting, Nausea and Related Symptoms 
Associated with Gastroparesis Using Enterra™ System
Gastroparesis is a stomach disorder character-
ized by delayed gastric emptying. Patients with 
gastroparesis suffer from a number of gastrointes-
tinal (GI) symptoms, including bloating, nausea, 
vomiting, early satiety, postprandial fullness, 
epigastric pain and heartburn. Gastroparesis 
has become an increasingly common medical 
condition among the United States population, 
affecting more than 1.5 million people. No cure 
for this disorder currently exists. 
Non-operative therapies for patients with 
gastroparesis include diet modification, drug 
therapy (including Prokinetics and Anti-emetics) 
and nutritional feeding via gastric or jejunal 
feeding tubes. However, these approaches can 
negatively affect the patient’s quality of life. 
Surgical procedures include gastrectomy, pyloro-
plasty and gastrojejunostomy. However, these 
procedures have provided limited success and are 
prone to complications.
The George Washington University Medical 
Center is one of 10 clinical sites in the U.S. par-
ticipating in a novel treatment study for patients 
with gastroparesis. Currently, 50 patients are 
enrolled in the study, with plans to enroll more 
patients in the future. This clinical trial is a 
double-blinded, randomized study to evaluate 
the safety and effectiveness of gastric stimula-
tion on the frequency of nausea and vomiting 
in patients with gastroparesis. The procedure 
involves a surgical implant of an Enterra™ elec-
trical stimulator, provided by Medtronic, Inc., 
onto the body of the stomach. Interim results of 
the clinical trial, organized by Medtronic, show 
that gastric stimulation reduces symptoms of 
nausea and vomiting in patients for whom drug 
therapy was unsuccessful. The goal of this study 
is to induce a sustained reduction in the often 
debilitating symptoms of this disease. 
Patients were asked to fill out a monthly 
diary of their symptoms prior to surgery to assess 
their baseline frequency of nausea and vomiting, 
early satiety, bloating, postprandial fullness, 
epigastric pain, epigastric burning, chest pain 
and chest burning. Several study-related tests 
are performed to determine if the patient quali-
fies for the study. An implant is placed inside 
the abdomen onto the body of the stomach and 
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the electrical stimulation begins at the time of 
surgery. After six weeks, patients are randomized 
to either the “On” or “Off” position for three 
months, then set to the opposite group for three 
additional months. Patients are required to attend 
scheduled follow-up appointments at three, six, 
nine and 12 months post-implantation and annu-
ally thereafter until the study is closed. At each 
follow-up appointment, subjects are assessed for 
symptom severity, frequency, complications and 
adverse events, health status, quality of life and 
normal daily activities. The following symptoms 
are assessed using a Likert scale of zero (absent) 
to four (extremely severe): vomiting, nausea, early 
satiety, bloating, postprandial fullness, epigas-
tric pain, epigastric burning, chest pain, chest 
burning and other symptoms.
The results from baseline to 12 months noted 
a decrease in the frequency of vomiting, nausea, 
early satiety, bloating, postprandial fullness, epi-
gastric pain, epigastric burning, chest pain, chest 
burning and other symptoms. Secondly, there was 
a significant decrease in vomiting at each follow 
up appointment: three, six, nine and 12 months. 
Lastly, there was a significant decrease in the total 
severity scores and frequency scores at each three 
month interval up to 12 months. 
This study demonstrated that Enterra™ 
gastric stimulation is an effective and safe treat-
ment option for the reduction of the severity 
and frequency of symptoms associated with 
gastroparesis. This treatment has improved the 
quality of life for many people and has allowed 
them to carry out a normal lifestyle and feel in 
control of their symptoms. Results of this study 
will be used to support a pre-market approval 
application (PMA) to the U.S. Food and Drug 
Administration. 
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Breast-Specific Gamma Imaging as an Adjunct Modality for the 
Diagnosis of Invasive Breast Cancer
Mammography has remained the modality 
of choice for breast cancer screening with a 
sensitivity of 78-85 percent.1-4 However, this 
percentage declines significantly for women 
with dense breasts and sub-centimeter cancers. 
Limitations such as these have resulted in the 
development of adjunct imaging modalities to 
improve breast cancer detection. 
One such method involves nuclear medicine 
techniques, in which physiological properties 
of tumors are utilized to effectively make a 
diagnosis. Most common among these is the 
use of 99mTc-Sestamibi with a general purpose 
gamma camera. Although 
this modality has improved 
breast cancer detection by 
a large margin, it has been 
found to be inadequate in 
the discovery of non-palpable 
lesions and those less than 
one centimeter in size 
due to intrinsic resolution 
limitations.5–8 
To resolve these difficulties, a small field-
of-view camera was developed that allows 
high-resolution detection of breast lesions.9 This 
technique, Breast Specific Gamma Imaging 
(BSGI), is a substantial improvement over the 
general purpose gamma camera model. The 
design of BSGI allows one to reliably image sub-
centimeter lesions due to its improved resolution 
and shape which is optimized for breast imaging. 
Furthermore, images acquired from the device are 
in projections correlated to the medial-lateral and 
craniocaudal views of traditional mammography, 
allowing images to be interpreted in a straightfor-
ward manner. Until now, there have been limited 
studies defining the sensitivity of this emerging 
modality. This study is the largest to date, deter-
mining the sensitivity of BSGI for the diagnosis 
of invasive breast cancer.
Our project was a retrospective review of 139 
consecutive women with biopsy-proven invasive 
carcinoma from November 2004 to June 2007. 
The images acquired from the BSGI were sub-
jectively categorized based on the degree of focal 
radiotracer uptake. Lateralization and region of 
the focal area of increased radiotracer uptake were 
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noted and compared to the laterality and location 
of the biopsy proven invasive cancer. The clinical 
report in the patient’s record was used for BSGI 
interpretation and cases were not reinterpreted for 
the study.
Out of the 149 invasive cancers identified, 146 
were recognized with BSGI, totaling a sensitivity 
of 98 percent for the BSGI detection of invasive 
breast cancers. There were three cancers unidenti-
fied by BSGI, each being of grade 1 histology and 
sub-centimeter lesion size. One explanation for 
the inability of BSGI to find these three patho-
logically proven invasive cancers may be due to 
the posterior and otherwise 
difficult to image area of 
the breast. In the case of 
one patient, the small size 
of the breast along with 
a posterior location may 
be the cause for the non-
visualization of the lesion. 
Despite these limitations, 
BSGI was still able to 
identify 40 percent (2/5) sub-centimeter, grade 1 
tumors. Moreover, our study showed four out of 
149 infiltrating ductal carcinoma cases that were 
pathologically categorized as multifocal. BSGI 
was able to correctly identify the multifocality in 
all instances.
Our results demonstrate that BSGI is a highly 
sensitive method of diagnosing invasive breast 
cancer. This study, using the largest sample size of 
invasive cancers studied with BSGI to date, along 
with data in the literature, also suggests that 
BSGI is a reliable adjunct imaging modality.
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FIGURE 1: BREAST SPECIFIC 
GAMMA IMAGING. Patient 
with a multifocal infiltrating ductal 
carcinoma of the left breast seen 
as separate areas of increased 
radiotracer uptake in the craniocaudal 
view.
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Religious Experience in Epilepsy
The ancient association between epilepsy and 
having a concurrent religious/spiritual experience 
has persisted through the ages and remains 
to the present day. People with epilepsy have 
been reported to have heightened religious 
experiences and spiritual orientations from 
a clinical perspective. In particular, people 
with temporal lobe epilepsy (TLE) have been 
described as intensely religious, preoccupied with 
the study and practice of spirituality/religion 
and frequently report intense spiritual/religious 
experiences. Waxman and Geschwind (1975) 
proposed an Interictal TLE Personality citing 
“hyperreligosity,” an excessive preoccupation 
with religion/spirituality, as a distinct behavioral 
trait among its probable characteristics.1
The TLE Interictal Personality was further 
investigated by Bear and Fedio (1977) using 
a structured personality inventory and hyper-
religiousness was among the set of 18 personality 
traits consistently observed in TLE patients.2 
The proposition of an interictal TLE Personality 
has been controversial and our attempt to verify 
this syndrome, in addition to other studies, have 
been met with mixed results. 
Our study evaluated the religiousness/
spirituality of TLE patients as compared with 
patients with primary generalized epilepsy 
and other types of focal epilepsy to determine 
whether TLE patients are more religious/spiritual 
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than other epileptics. We hypothesized that TLE 
predisposes individuals to a heightened sense of 
religiousness/spirituality, also associated with 
neuroplastic changes, the net effect of which is to 
enhance sensory activation of the limbic system. 
A systematic survey of religious experience in 
epilepsy, with a focus on TLE, was conducted 
with a more comprehensive questionnaire 
on spirituality/religion than previously 
administered. 
Data for this study was collected from 
adults admitted to the New York University 
Comprehensive Epilepsy Center inpatient 
video-EEG monitoring unit between April 16, 
2001 and Sept. 16, 2002. The study population 
consisted of 151 patients with various types 
of epilepsy. The Brief Multi-Dimensional 
Measure of Religion/Spirituality for use in 
Health Research (BMMRS) was used to assess 
individual religiousness/spirituality.3 The 
BMMRS is a 39-item questionnaire developed 
by the Fetzer Institute in association with 
the National Institute on Aging (1999) that 
examines 11 different domains of religiousness/
spirituality which have been identified as related 
to physical and mental health. 
We found TLE patients are no more 
religious/spiritual than other epilepsy patients 
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and report fewer religious conversion experiences. 
Upon comparison of the study population with 
the BMMRS normative population distribution 
data from the 1998 General Social Survey, we 
found epilepsy patients as a whole are more 
religious/spiritual than the general population.4
Our findings refute the purported 
“hyperreligiosity” associated with TLE. No 
direct causal relationship can be established 
between seizure discharges in the temporal lobe 
and deepened religiousness/spirituality. The 
religious/spiritual preoccupation and intense 
religious conversion experiences proposed as 
part of the constellation of TLE personality 
traits is not supported by our data. Heightened 
religiousness/spirituality may be a trait common 
among all epileptics, regardless of epilepsy type 
and seizure origin. 
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FIGURE 1: BMMRS 
DOMAIN SCORES 
REPRESENTED 
BY OUR STUDY 
POPULATION 
(TLE SUBJECTS) 
VS. THE GENERAL 
POPULATION (GSS 
SAMPLE). Scores are 
scaled from 0-100 with higher 
scores indicating experiences 
with a greater degree of 
religiousness/spirituality. 
*Significant Differences (p 
value < .05) in the BMMRS 
mean scores of TLE subjects vs. 
the general population (GSS 
Sample) were found in nine out 
of the 11 BMMRS domains: 
Daily Spiritual Experiences 
(p < .0001); Religious/
Spiritual Values and Beliefs 
(p < .0001); Forgiveness 
(p < .0001); Private Religious/
Spiritual Practices (p < .0001); 
Positive Religious/Spiritual 
Coping (p = .0010); Positive 
Religious/Spiritual Support 
(p < .0001); Organizational 
Religiousness (p = .0017); 
Negative Religious/Spiritual 
Support (p = .0430); Overall 
Self-Ranking (p < .0001).
There were no significant 
differences in Religious/Spiritual 
History and Negative Religious/
Spiritual Coping domains.
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A Geometrical Forefoot Model: Relationship to Foot Function
In collaboration with the Motion Analysis 
Laboratory of Leon Root, MD, biomechanical 
foot function was studied using a geometrical 
forefoot model designed to assess and treat pedal 
pathology. Malleolar valgus index (MVI) and 
center of pressure excursion index (CPEI) were 
developed to measure static and dynamic foot 
function.1 Many sophisticated and complex foot 
models have been created, however, none have 
been used for clinical decision making.2,3 A sim-
plified mathematical approach was developed by 
Demp to model metatarsal length patterns from 
dorsoplantar X-rays by unique conic curves and 
their eccen-
tricities.4,5 Our 
study explores 
the association 
between these 
model param-
eters and the 
biomechanical 
foot function 
in healthy 
asymptomatic 
individuals.
The Demp 
forefoot model 
(Figure 1) 
constructs a conic curve through the meta-
tarsophalangeal joint (MTPJ) centers. Five 
MTPJ x,y coordinates are used to solve the 
equation for a unique conic curve:
AX2 + BX + CXY + DY + EY2 = 0
where A, B, C, D and E are the resulting 
five coefficients. In this study, medial and lateral 
aspects of each MTPJ were calculated with a 3-D 
digital pointer. The midpoint of each medial and 
lateral MTPJ joint space was considered to be 
the MTPJ center. A forefoot coordinate system 
was generated such that the x-axis projected from 
the fifth MTPJ to the first MTPJ, the y-axis 
was perpendicular to that vector, and the origin 
was at the fifth MTPJ. Using Maple software, 
conic curves were created and the possible curve 
types were: ellipse, parabola and hyperbola. 
Eccentricity, which is a constant that describes 
the shape of a conic curve, was calculated as 
follows:
E = (P x F1)/(P x D1) = (P x F2)/(P x D2)
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where P is the pressure, F is the focus and D 
is the distance from the center to a vertex. We 
hypothesized that feet with normal rectus align-
ment and function had a hyperbolic conic curve 
describing their MTPJ relationships with an 
eccentricity greater than one.4,5
Barefoot plantar pressures were measured 
during one’s comfortable walking speed with 
the Novel emed X system. The plantar loading 
parameters (peak pressure, peak force, pressure-
time integral) were measured in each anatomical 
region of the foot (hallux, first–fifth MTPJs, 
medial arch, lateral arch, medial heel and lateral 
heel) using a masking algorithm. In Figure 2, the 
maximum pressure throughout the stance phase 
of a healthy asymptomatic person (right) and a 
person with diabetes and HV (left) is illustrated. 
The areas of high pressure are indicated by the 
arrows. Note that 
the subject with 
diabetes and HV has 
higher plantar pres-
sures and a reduced 
CPEI indicative of 
overpronation as 
compared with the 
healthy individual. 
Using our simplified 
geometric forefoot 
model, conserva-
tive or surgical 
treatments may be 
modified to optimally convert a pathological foot 
to a healthy asymptomatic foot with improved 
biomechanical function.
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FIGURE 1: CONIC 
CURVE MODEL. 
FIGURE 2: 
PEAK PLANTAR 
PRESSURES: healthy 
(right), HV (left).
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Barriers to Therapeutic Cancer Vaccine Development
Therapeutic cancer vaccine development is 
an exciting and rapidly evolving discipline of 
biotechnology. However, it is undoubtedly bur-
dened by a variety of obstacles that need to be 
addressed before success can be achieved.
Therapeutic vaccines energize the body’s 
immune system to recognize and attack estab-
lished tumors that are otherwise ignored by 
normal physiologic immune surveillance.1 
Prophylactic vaccines, on the other hand, are 
administered to healthy individuals and are 
designed to prevent infection from cancer-
causing viruses.2
As of August 2007, two prophylactic cancer 
vaccines had been approved by the Food 
and Drug Administration (FDA). In 2000, 
ENGERIX-B was 
approved to prevent 
primary liver cancer 
as a result of chronic 
hepatitis B infection. 
In 2006, Gardasil was 
approved to prevent 
infection from some of 
the most common strains 
of human papillomavirus that cause cervical 
cancer.2 Currently, the scope for cancer prophy-
laxis is limited because few cancers are caused by 
viruses.3
Therapeutic cancer vaccines, however, have 
the potential to combat nearly any type of estab-
lished tumor. Yet, so far none have reached the 
market by earning FDA approval.4,5 This lack of 
success can be attributed to both scientific and 
regulatory barriers.
As a collection of altered self cells, tumors 
contain many of the same identification markers 
as normal cells of that tissue. That, in part, 
makes it difficult to convince the immune system 
to attack and eradicate tumors.6 While a variety 
of tumor-associated antigens have been identified 
and many immunotherapeutic strategies have 
been tested, objectively defined clinical responses 
are rare. The reasons for this include the inability 
of current approaches to generate efficient 
T-cell responses, the presence of regulatory cells 
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that inhibit T-cell responses and tumor escape 
mechanisms.7
While scientific innovation remains the prin-
cipal factor for determining success, a paradigm 
shift in three regulatory factors could greatly 
facilitate the development process.
First, the current regulatory system is geared 
to support single-agent drug approvals, yet 
combinations may be necessary. There is an 
increasing trend in therapeutic vaccine develop-
ment toward the use of multiple antigens and 
adjuvants. Attacking cancers from several angles 
may yield synergistic and clinically significant 
results.1
Second, traditional efficacy endpoints, which 
are based on quantitative tumor assessments, 
may not always adequately assess clinical benefit 
(i.e., survival and quality of life). Tumor response 
and patient response are not necessarily mutually 
inclusive.8 Thus, when a candidate vaccine meets 
specified safety standards, various efficacy criteria 
should be considered to account for this potential 
discrepancy.
And third, current designs of clinical trials 
can be made more efficient and effective. The 
adaptive clinical trial approach, which employs 
Bayesian statistical methods, offers a scientifi-
cally rigorous alternative to the classic design.9 
This approach is suitable in studies as informa-
tion accrues during a trial, potentially allowing 
for smaller and more informative trials and 
enabling patients to receive better treatments. 
Furthermore, this approach better handles com-
bination therapies and multiple endpoints.10
Implementing these changes may help 
bring quicker approvals of safe and efficacious 
While a variety of tumor-associated antigens have been 
identified and many immunotherapeutic strategies 
have been tested, objectively defined clinical responses 
are rare. 
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therapeutic cancer vaccines. That, in turn, 
would encourage further innovation, leading to 
improved treatments that can increase the dura-
tion and improve the quality of life.
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Increasing Awareness and Access to Emergency Contraception
Each year, approximately 750,000 to 850,000 
adolescent women become pregnant in the 
United States, and of these pregnancies, 74 to 95 
percent are unintended or unwanted.1 Teenage 
mothers are less likely to receive timely prenatal 
care and are more likely to smoke during 
pregnancy. Babies born to teenage mothers are 
at increased risk of low birth weight, pre-term 
birth, serious chronic illnesses or developmental 
delays.2 Due in part to these significant 
outcomes, understanding teen pregnancy and 
assisting teens who wish to delay childbearing is 
an issue of increasing public health and medical 
importance.
Recent estimates suggest that approximately 
46 percent of high school students and 80 
percent of college students between 18 and 24 
have had sex.3 The National Longitudinal Study 
of Adolescent Health found that sexual activity 
during adolescence is associated with inconsistent 
or no use of contraception.4 Marginalized 
youth, including youth of color, youth in foster 
care, and low-income youth are more likely 
to be confronted with financial, cultural and 
institutional barriers to obtaining health care 
which may contribute to their increased risk of 
negative sexual outcomes.5 Developing health 
programs to address teen pregnancy, especially 
among high-risk populations, is a major 
challenge requiring multi-level approaches.
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In 2006, the Harlem Health Promotion 
Center (HHPC) began developing an 
Emergency Contraception (EC) awareness 
campaign to address the dire need for enhanced 
contraception options amongst its high-risk 
Black and Latino patient populations. To 
date, there is a deficiency in culturally specific 
and tailored intervention materials for this 
population, and research indicates high rates of 
teen pregnancy coupled with a lack of awareness 
about EC.6 This project titled “EC as 1, 2, 3” 
utilizes community-based participatory research 
and social marketing techniques. 
This model relied on a youth development 
theory, and allowed youth to actively participate. 
For the summer of 2006, a group of 10 Black 
and Latino “youth experts” between the ages 
of 15 and 20 were selected to participate. These 
“experts” assisted with major tasks, including 
incorporating the findings of formative research 
with experiential knowledge. The participants 
also worked with a Harlem-based filmmaker 
and design students from Parsons New School 
of Design. Additionally, as the Youth Advisory 
Board Coordinator, I developed and coordinated 
a comprehensive youth development curriculum 
which included leadership and professional 
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development, critical social analysis and media 
training for the affiliated youth. 
In May 2007, the project materials, which 
included an educational DVD, brochure, 
posters and Web site were launched for use with 
the Center’s Mobile Health Team outreach to 
high-risk youth and for use 
in training and educational 
sessions with medical, nursing, 
and public health students and 
clinical providers. The overall 
project succeeded in producing 
outstanding educational 
materials for youths. As one 
youth stated, “they were ready 
to hear our voice and make it 
an echo for change.”
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FIGURE 1: ADVERTISEMENT FOR “EC AS 1,2,3” CAMPAIGN 
FOR EMERGENCY CONTRACEPTION.
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Medical Relief Efforts in Jammu, India
Since India attained independence in 1947, 
Jammu and Kashmir have been in a state of polit-
ical and social turmoil due to tensions between 
Hindus and Muslims. In 1990, tensions between 
the groups peaked and many families had no 
choice but to leave their homes and start fresh. 
Seventeen years later, Kashmiris are still trying 
to get their lives back together and move on from 
the terror they experienced. 
In the summer of 2007, I traveled with sup-
port from the American Association of Physicians 
of Indian Origin to Jammu, India. Under the 
guidance of Dr. K.L. Chowdhury and his staff, 
I worked inside migrant camps and at the Shirya 
Bhatt Charitable Hospital in Jammu, India.
Diabetes has increased in prevalence within 
the Kashmiri migrant community. About 25 
percent of the adult population aged 18 and over 
suffers from diabetes, and nearly 33 percent from 
hypertension. The clinic suggested gathering 
information on the management costs of dia-
betes in terms of medications and monitoring, 
as well as the type of diet and the current blood 
glucose levels. I prepared a survey and went to 
the “quarters” of about 80 families and found 
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that approximately 25 percent of their monthly 
income went toward diabetes medications and 
blood sugar testing for one person. 
More valuable was learning about the lifestyle 
changes each family made upon migration. Each 
family was given a 10' by 15' room in which to 
live in. A group of about 10 families was expected 
to use one communal 
bathroom, one water 
pump and to live without 
privacy from their neigh-
bors. In that one room, 
children would sleep, 
play and study while 
their parents cooked and 
washed clothes. 
Health care was also 
a luxury. I remember 
coming across a man 
lying on the dirt floor in 
front of his quarter with 
a measured hemoglobin 
of 3 and fever of 104 
degrees. His children, 
ages 10 and 8, stood 
above his head, his wife 
and mother pressing 
his feet and legs. His 
elder brother stared at 
him with fear in his eyes. His pale skin and weak, 
unmoving body made me think he was going to 
pass away before me. The nearest hospital was 
20 miles away, and there was no ambulance to 
take him, nor were the funds available to pay for 
his care. A previous doctor had recommended a 
blood transfusion, but there was no Type A blood 
type match in his family. 
As a medical student, I was unable to help. I 
could not offer any physical comfort. Instead, he 
gave something to me. He reaffirmed my reasons 
for aspiring to become a physician: to provide 
relief and support. I want to work in this type 
of community: where resources are sparse, and 
the need is great. Dr. Chowdhury and his staff 
amazed me with their tireless efforts to aid this 
community and demonstrated how effort and 
passion can create positive change.
FIGURE 1: MOTHER BATHING HER DAUGHTER AT A WATER PUMP IN 
A MIGRANT CAMP IN JAMMU.
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A Place of Learning: The Mondaña Clinic, Ecuador
During the three-hour canoe ride to Mondaña, 
the sun pierces through the dense foliage of the 
Ecuadorian rain forest as the canopy rises and 
falls along the river’s shore. My goals while in 
this beautiful setting were to involve myself in 
the community healthcare system and patient 
population through education, conversation 
and treatment. In the 
quiet of the headwind, 
I wondered what 
challenges lay ahead.
The Mondaña 
Clinic was started in 
1995 by The Yachana 
Foundation to address 
the needs of a large, 
medically underserved 
population. The 
Clinic, located along 
the Upper Napo River 
in the Ecuadorian 
rain forest, now 
serves local Mondaña 
and 25 surrounding 
communities, with 
a patient population 
of more than 10,000. 
These communities 
are spread over a wide 
geographic area, many 
accessible only by canoe or long hikes, making 
access to health care difficult. Nonetheless, the 
clinical staff makes regular visits. I traveled on 
such a visit and was privileged to share meals 
with families where I learned about the local 
history, culture and health. The Mondaña 
Clinic is the cornerstone of health care in the 
area, and visits are a critical part of the Clinic’s 
responsibilities. They represent the beginnings 
of a growing effort to provide for marginalized 
populations within remote regions of Ecuador.
In the Clinic, the lack of modern diagnostic 
technology forces doctors to rely on signs and 
symptoms to differentiate diagnoses and treat 
patients. I was challenged to learn these practical 
skills promptly. During my time in the rain 
forest, I saw a variety of illnesses, the most 
common of which were parasitic infections, 
the common cold or gripe, and malnutrition. 
I learned a great deal about the ways in which 
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these illnesses are being addressed and treated. 
For example, because many of these communities 
have no running or potable water, the Yachana 
Foundation developed a cheap water filtration 
system to improve community sanitation 
and thereby reduced parasitic and bacterial 
infections. To address insufficient health 
education, I spent 
time teaching and 
interacting with the 
students from the local 
Yachana High School. 
I had the opportunity 
to discuss health and 
hygiene and to design 
and implement a first 
responder and sex-
education course.
The Yachana 
Foundation was 
started to address 
the health care needs 
of the underserved 
communities along 
the Upper Napo 
River and has now 
broadened its focus 
to include education, 
eco-tourism, rain forest 
conservation, micro 
enterprise and micro lending. The Foundation is 
so deeply involved in the lives of the surrounding 
communities that it has become an integral 
part of health, education and preservation 
of the Upper Napo River. This was a unique 
opportunity for me to learn about and make 
an impact on the health care and education of 
a large, underserved community. I observed, 
firsthand, what one organization is doing to 
preserve one of the world’s richest biological 
resources and improve the lives of its inhabitants. 
It came as no surprise to me when I discovered 
that, in the indigenous Quichua language, the 
word Yachana means, “a place of learning.”
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FIGURE 1: APPROXIMATE LOCATION OF THE 
MONDAÑA CLINIC IN ECUADOR.
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Development of a Longitudinal Genetics Curriculum
Genetics is an ancient science. Yet, recently, with 
the description of the DNA molecular structure 
and the completion of the sequencing of the 
human genome, much more information relevant 
to the practice of medicine is being revealed. The 
evolution of the field from a basic descriptive 
science of Mendelian genetics, drosophila and 
other organisms, to cancer biology, molecular 
immunology, cardiovascular genomics and 
pharmacogenomics has made the management 
of curricula change in U.S. medical schools seem 
slow and fragmented. The ensuing gap between 
available information and knowledge of medical 
students, residents and practitioners, poses a chal-
lenge for teaching and the dissemination of this 
vital information.  
Although most medical schools have devel-
oped genetics courses for first- and second-year 
medical students, the integration of basic science 
and clinical medicine has lagged. In addition, 
exposure to genetics in the early years of medical 
school and having to recall and apply it in the 
clinical years is a difficult task for most students. 
This educational shortcoming calls for the imple-
mentation of a genetics curriculum for medical 
students in their clinical years. Addressing this 
disparity in genetics education during the med-
ical school years can improve the knowledge base 
of future clinicians in these regards. 
In recognition of this educational deficit, 
researchers at The George Washington University 
School of Medicine and Health Sciences (SMHS) 
designed a genetics curriculum for third-year 
medical students. A needs assessment, and 
pre- and post-test about medical genetics was 
developed. As a pilot study, the survey and pre-
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test were administered to third-year students 
during their OB/GYN clerkship. The curriculum 
in genetics reinforced genetic concepts learned 
in the first two years of medical school and 
introduced their clinical application. The cur-
riculum, administered through Blackboard®, was 
case-based using an organ-system approach, and 
introduced students to relevant online genetics 
resources. Students were presented clinical 
vignettes on genetic diseases and answered clini-
cally relevant questions about these disorders. 
The curriculum was designed with principles 
of adult learning theory to emphasize skills in 
self-directed learning. After com-
pleting the curriculum, students 
took a post-test and their scores 
were compared to their pre-test 
scores. Students then completed 
an exit survey. In the pilot study, 
17 students completed the needs 
assessment, and pre- and post-test. 
Twelve of 17 students showed 
improved scores, with a mean 
increase of 11.5 percent. Five of 17 
failed to demonstrate improvement, 
with a mean decline of 4.5 percent.
Pre-curriculum medical student surveys 
indicated deficient knowledge and comfort with 
genetics. Ninety-seven percent of the students 
were comfortable speaking with patients about 
family history, but 31 percent did not feel com-
fortable speaking about a diagnosis of a genetic 
disease. In the exit survey, students expressed the 
need for a more robust genetics education cur-
riculum beginning in the second year. They indi-
cated overall satisfaction with our experimental 
curriculum, particularly the online resources, and 
recommended its future use. 
The addition of this curriculum into the cur-
rent GW SMHS curriculum would make medical 
genetics education more longitudinal, reinforce 
genetics concepts in a clinical setting, and assist 
students in developing self-directed learning skills 
to be better equipped to find genetics information 
throughout their careers. The curriculum will 
be administered to 180 GW medical students 
between July 2007 and June 2008.
Pre-curriculum medical student surveys indi-
cated deficient knowledge and comfort with 
genetics. Ninty-seven percent of the students were 
comfortable speaking with patients about family 
history, but 31 percent did not feel comfortable 
discussing a diagnosis of a genetic disease.
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